Function of MicroRNA-146a and NF-κB in Physiologic and Pathologic Hematopoiesis by Zhao, Jimmy Liu
 
Function of MicroRNA-146a and NF-κB in Physiologic 
and Pathologic Hematopoiesis 
 
 
 
Thesis by 
Jimmy Liu Zhao 
 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
2013 
Defended February 5, 2013 
 
 
 ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2013 
Jimmy Liu Zhao 
All Rights Reserve
 iii
ACKNOWLEDGEMENTS 
I want to thank Professor David Baltimore for providing great mentorship and training over the years. I 
also want to thank Dr. Dinesh Rao for excellent mentorship and Drs. Ryan O’Connell, Alejandro 
Balazs, Devdoot Majumdar, Parameswaran Ramakrishnanand, Lili Yang, Shengli Hao, Aadel 
Chaudhuri, Arnav Mehta, Yvette Garcia, and other members of the Baltimore Lab for tremendous help 
and stimulating discussion over the years. I also want to thank members of my thesis committee, Paul 
Patterson, Sarkis Mazmanian, David Baltimore and Dinesh Rao, as well as UCLA MSTP directors, 
Steve Smale and Kelsey Martin, for guidance and mentorship. Lastly, I’d like to acknowledge the staff 
at the California Institute of Technology animal facility, FACS Core sorting facility and genomic core 
facility for excellent technical support. NFκB-GFP reporter mice were a generous gift of Dr. Christian 
Jobin at the University of North Carolina, Chapel Hill. My training experience and research work were 
significantly enriched and enhanced by wonderful collaborations with Chao Ma of the Heath Lab and 
Beverly Lu of the Tirrell Lab at Caltech, and many external collaborators from other institutions. The 
work was supported by research grant R01AI079243 (D.B.), National Research Service Award 
F30HL110691 and the UCLA/Caltech Joint Medical Scientist Training Program (J.L.Z.), from the 
National Institute of Health.  
 
 
 
 
 
 
 
 iv
ABSTRACT 
During inflammation and infection, hematopoietic stem and progenitor cells (HSPCs) are stimulated to 
proliferate and differentiate into mature immune cells, especially of the myeloid lineage. MicroRNA-
146a (miR-146a) is a critical negative regulator of inflammation. Deletion of the gene encoding miR-
146a—expressed in all blood cell types—produces effects that appear as dysregulated inflammatory 
hematopoiesis, leading to a decline in the number and quality of hematopoietic stem cells (HSCs), 
excessive myeloproliferation, and, ultimately, to exhaustion of the HSCs and hematopoietic 
neoplasms. Six-week-old deleted mice are normal, with no effect on cell numbers, but by 4 months 
bone marrow hypercellularity can be seen, and by 8 months marrow exhaustion is becoming evident. 
The ability of HSCs to replenish the entire hematopoietic repertoire in a myelo-ablated mouse also 
declines precipitously as miR-146a-deficient mice age. In the absence of miR-146a, LPS-mediated 
serial inflammatory stimulation accelerates the effects of aging. This chronic inflammatory stress on 
HSCs in deleted mice involves a molecular axis consisting of upregulation of the signaling protein 
TRAF6 leading to excessive activity of the transcription factor NF-κB and overproduction of the 
cytokine IL-6. At the cellular level, transplant studies show that the defects are attributable to both an 
intrinsic problem in the miR-146a-deficient HSCs and extrinsic effects of miR-146a-deficient 
lymphocytes and non-hematopoietic cells. This study has identified a microRNA, miR-146a, to be a 
critical regulator of HSC homeostasis during chronic inflammatory challenge in mice and has provided 
a molecular connection between chronic inflammation and the development of bone marrow failure 
and myeloproliferative neoplasms. This may have implications for human hematopoietic malignancies, 
such as myelodysplastic syndrome, which frequently displays downregulated miR-146a expression.  
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OVERVIEW and SCIENTIFIC BACKGROUND 
MicroRNA 
Initially discovered by the Ambros and Ruvkun labs in the early 1990s, microRNAs (miRNAs) have 
emerged as important regulators of gene expression 1-2.  In the past several years, significant advances 
have been made with regards to understanding their integration into molecular networks that control 
cellular development and function. In the hematopoietic system, several individual miRNAs have 
emerged as important regulators of physiological and pathologic myeloid development and function. 
MiRNAs are encoded within exons of unique non-coding genes, or sometimes within introns of 
protein-coding genes, and are most often transcribed from the genome by RNA polymerase II. Some 
miRNAs exist as clusters and are encoded on the same primary transcript. The primary transcript (pri-
miRNA) is processed by the ribonuclease Drosha/DGCR8 in the nucleus and then transported into the 
cytoplasm as a pre-miRNA, which contains the miRNA stem-loop structure. For most miRNAs, this 
serves as a substrate for the endoribonuclease Dicer, which creates a double-stranded short RNA that is 
unwound and then loaded into the RNA-induced silencing complex (RISC) (reviewed in 3-4). This 
“classical” description of miRNA biogenesis was true for all known miRNA until mid-2010, when two 
seminal papers reported that Dicer independent production of miRNAs could occur via the “slicer” 
RNAse function of Argonaute 2 (Ago2), a component of the RNA induced silencing complex (RISC)5-
6. The mature miRNA is loaded onto the RISC, a multi-protein complex that includes members of the 
Argonaute protein family 7. Once in the RISC, the mature miRNA interacts with a target mRNA via 
the latter’s 3’UTR. Structural, biochemical and bioinformatics analyses indicate that a 6-nucleotide 
seed sequence at the 5’ end of the miRNA is important in mediating the interaction with its target 8. In 
most cases, miRNAs repress their targets and this change is detectable at the RNA level, and it is now 
thought that this represents the majority of the change induced by miRNAs 9-10. It should be noted that 
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there are scattered reports of miRNAs that interact with their targets in a non-3’UTR-dependent or 
non-seed-dependent fashion, and miRNAs that cause upregulation of “targets” 11-12.  These studies 
suggest that there are aspects to miRNA function that remain elusive. Initial studies revealed the global 
importance of miRNAs in hematopoiesis. Dicer deletionin the hematopoietic lineage leads to marked 
defect in competitive repopulation assays and the deletion of Ago2 leads to severe problems with 
erythroid and B-cell development 13-14. However, the main focus of research in the field has been on 
examining how individual miRNAs are integrated into various regulatory pathways in myelopoiesis. 
miRNAs are induced by transcription factors and other genes involved in myelopoiesis. For example, 
PU.1 induces expression of miR-223 and NF-kB induces expression of miR-155 and miR-146a. 
miRNAs, in turn, repress the expression of their targets, for example, miR-155 regulates PU.1 and 
C/EBP-β, thereby changing the transcriptional profile of the cell 15. In this search for targets, global 
RNA expression profiling followed by correlation with algorithmic target prediction has been fruitful 
15. Confirmation of the targets on a case-by-case basis can then be followed by functional analyses of 
the regulated pathways.   
 
MicroRNA-146a 
MicroRNA-146a (miR-146a) along with miR-146b form a highly conserved two-member miRNA 
family. MiR-146a and miR-146b are located on chromosome 5 and 10, respectively, in the human 
genome and on chromosome 11 and 19, respectively, in the mouse genome. In 2006, miR-146a first 
came to our attention in a systemic microarray screen to identify miRNAs that are involved in innate 
immune activation 16. Stimulating THP1 cells, a human monocytic cell line, with lipopolysaccharide 
(LPS) was found to selectively upregulate the expression of three miRNAs, miR-155, miR-146 and 
miR-132. Since then, we have been focused on investigating the function of miR-155 and miR-146 in 
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the immune system. In the hematopoietic system, the expression of miR-146a is relatively low in 
progenitor cells and increases modestly with maturation. However, in certain specialized cell types, 
such as Ly-6Clo monocytes and epidermal Langerhans cells, miR-146a is constitutively expressed at a 
high level (17-18 and immunological genome project http://www.immgen.org/). In addition, miR-146a 
expression is up-regulated upon stimulation of myeloid cells with microbial components and pro-
inflammatory cytokines.  MiR-146a is also stimulated upon activation of T cells with T-cell receptor 
antigens 19-21. Viral and fungal infection also induces miR-146a expression 22-24. Basal and induced 
expression of miR-146a is regulated by several important transcription factors in immune cells. Our 
initial characterization of miR-146a promoter locus identified two consensus NF-κB binding sites that 
were shown to be important in transcriptional activation of miR-146a in myeloid cells in response to 
inflammatory stimulation; mutations of these consensus sequences abolished the promoter activity in a 
luciferase reporter system 16. Subsequent studies showed that downregulation of NF-κB activity 
chemically or genetically inhibits basal and induced expression of miR-146a in macrophages and T 
cells, confirming the role of NF-κB in regulating miR-146a expression 20,22-23. In addition to regulation 
by NF-κB, expression of miR-146a is also regulated by lineage-dependent transcription factors. During 
myeloid differentiation, PU.1 works together with NF-κB to control the basal expression of miR-146a 
through dynamic occupancy at the promoter region 18,25. In lymphocytes, the lineage-specific 
regulation of miR-146a may be fulfilled by other transcriptional factors, such as c-ETS 24,26. In 
addition to transcriptional activation, miR-146a expression may be repressed in a lineage specific 
manner. This was shown in the example of megakaryocyte differentiation, where PLZF upregulation 
interacts with the miR-146a promoter to inhibit its expression 27. A more extreme case involves global 
miRNA repression, including miR-146a, by the myc oncogenic transcriptional factor during 
lymphomagenesis 28. One interesting observation suggests estrogen can modestly downregulate miR-
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146a, but not miR-146b, in mouse splenic lymphocytes. However, it is not clear from the study 
whether the effect of estrogen on miR-146a expression is direct 29. Overall, basal miR-146a expression 
is regulated by a set of lineage-dependent transcription factors in a cell-lineage specific manner. This 
basal level can be further regulated in an activation-dependent manner by inducible transcription 
factors, such as NF-κB (Figure i). In comparison to miR-146a, the regulation of miR-146b expression 
is less understood. Some previous reports on miR-146b expression were performed primarily with 
hybridization-based methods, which may have not been specific enough to separate the mature 
sequences of miR-146a and miR-146b because they only differ by one nucleotide. Nevertheless, miR-
146b seems also to be induced by pro-inflammatory cytokines and dysregulated miR-146b expression 
is associated with several human non-hematologic cancers 30-35. In addition, in unpublished work, we 
have shown that miR-146b expression can be clearly detected by RT-qPCR in miR-146a-deficient 
bone marrow cells, indicating that it is not a pseudogene or undetectable in adult hematopoietic cells as 
previously suggested 19,36. 
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Figure i. Expression of miR-146a is regulated by a set of transcriptional factors in a cell-lineage 
specific manner, involving such factors as PU.1, c-ETS, and PLZF, and in an activation-dependent 
manner, involving such factors as NF-κB. Validated targets of miR-146a include Irak1, Traf6, Stat1 
and RelB, which are all involved in the NF-κB and STAT pathways, highlighting the role of miR-146a 
as a critical negative regulator of inflammatory and interferon signaling.    
 
MiR-146a Functions in Immunity  
Our initial report showed that miR-146a is highly up-regulated in human monocytes in a NF-κB-
dependent manner following toll-like receptor (TLR) stimulation 16. Initial sequence complementation-
based algorithms (e.g. TargetScan) identified TRAF6 and IRAK1 as targets of miR-146a. The 
regulation of these two proteins by miR-146a in monocyte/macrophages, T- and B- lymphocytes was 
then confirmed by 3’UTR luciferase reporter assays and gene expression analyses 16,19-20,22,37. Because 
TRAF6 and IRAK1 are known feedback regulators of the NF-κB signal pathway, a molecular circuitry 
involving miR-146a, TRAF6/IRAK1 and NF-κB is proposed to be important in the regulation of both 
innate and adaptive immunity 38. One of the first pieces of definitive evidence of this hypothesis came 
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from the study of miR-146a-deficient mice generated in our laboratory 19. Consistent with the proposed 
hypothesis, miR-146a-/- mice were found to be hyper-responsive to LPS challenge. Stimulation with 
sublethal level of LPS in vivo induced a higher serum level of pro-inflammatory cytokines— including 
TNFα and IL-6 and IL-1β— in miR-146a-/- mice than in wild type mice. In addition, miR-146a-/- 
mice experienced a higher mortality rate in response to minimal lethal LPS challenge. The hyper-
inflammatory response was also observed in bone marrow derived macrophages (BMDMs) from miR-
146a-/- mice in vitro. To complement the study on miR-146a-/- mice, enforced overexpression of miR-
146a in THP-1 cells resulted in an attenuated inflammatory response 19. Work of others has confirmed 
these general observations. These studies provide further support that miR-146a is an important 
negative regulator of innate immune activation, potentially by targeting TRAF6 and IRAK1 and by 
orchestrating the silencing of TNFα gene in human monocytic cell lines in the context of endotoxin-
induced tolerance 39-41. In addition to regulating pro-inflammatory cytokine production, miR-146a 
negatively regulates type I interferon (IFN) production in vesicular stomatitis virus-infected mouse 
peritoneal macrophages by targeting TRAF6, IRAK1 and IRAK2 through a RIG-I/NF-κB-dependent 
but TLR4/MyD88-independent pathway 22. A study in human peripheral blood mononuclear cells 
confirmed a role for miR-146a as a negative regulator of the type I IFN pathway 42. In a more elaborate 
example of cell-type-specific regulation by miR-146a in the innate immune system, miR-146a 
specifically controls the Ly-6Chi, but not Ly-6Clo, monocyte response during inflammatory challenge 
17. The regulation by miR-146a in this context is cell-intrinsic, apparently through directly targeting 
Relb, thus also connecting miR-146a to the non-canonical pathway of NF-κB activation. This study 
further substantiates the role of miR-146a in innate immunity by controlling monocyte functional 
heterogeneity during an inflammatory response. Given the hyper-inflammation and the exaggerated 
immune response in the absence of miR-146a, we would expect miR-146a-/- mice to be more resistant 
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to bacterial infection than wild type animals. Indeed, miR-146a-/- mice displayed a lower bacterial 
load upon infection with Listeria monocytogenes 17. The role of miR-146a in adaptive immunity is 
particularly well studied in T cells. Aging miR-146a-/- mice develop an autoimmune disorder with 
lymphadenopathy, lymphocyte infiltration in various organs and an activated T cell phenotype 19. We 
carried out detailed analysis in a subsequent study to understand the physiological role of miR-146a in 
regulating the T cell response to antigen stimulation 20. We showed that miR-146a-deficient CD4 and 
CD8 T cells are hyper-responsive following T-cell receptor (TCR) stimulation, as indicated by 
increased proliferation and survival, exaggerated activation phenotype and enhanced effector cytokine 
production. The regulation of cell-intrinsic T cell response upon TCR stimulation by miR-146a was 
shown to again be through the regulation of TRAF6/IRAK1 and NF-κB signaling. This study adds 
miR-146a to a list of well-known negative regulators of NF-κB, including IκBα and A20, acting 
following TCR activation and suggests that these feedback regulators function collaboratively to limit 
the extent and timing of activation, with each apparently fulfilling a crucial non-redundant role. These 
mice studies were supported by studies in human T cells showing that miR-146a overexpression 
impairs IL-2 production. However, contrary to our observation that TCR-induced apoptosis was 
reduced in miR-146a-deficient T cells and enhanced in T cells with miR-146a overexpression, 
activation-induced cell death seems to be inhibited by miR-146a overexpression in human Jurkat T cell 
cancer line 26. The discrepancy may be due to the differences between mouse primary T cells and 
human cancer cell lines or the level of miR-146a overexpression achieved in the two experimental 
systems. In addition to functioning in effector T cells in a cell-intrinsic manner, miR-146a also controls 
the regulation of Th1 responses by affecting regulatory T cell (Treg)-function 43. Treg cells maintain 
immune homeostasis by suppressing the inflammatory response and preventing an over-reaction. In 
Treg cells, expression of miR-146a, but not miR-146b, is much higher than that in naïve T cells. In 
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turn, miR-146a-deficient Treg cells are functionally defective in their ability to restrain effector T cells, 
leading to overproduction of IFNγ and autoimmunity. Stat1 appears to be a responsible target for miR-
146a in regulating Treg cells. This study revealed an important regulatory function of miR-146a in 
Treg cells, suggesting upregulation of miR-146a is required for Treg cells to properly control the 
IFNγ-mediated Th1 response. The results imply an interesting phenomenon, which is that excessive 
effector cytokine signaling in Treg cells can lead to their failure to suppress the corresponding cytokine 
response in effector T cells. Further studies are required to elucidate the mechanistic implications 
behind this type of Treg cells/effector T cells regulation. Our knowledge of the function of miR-146a 
in B cells is limited. One study has provided evidence for miR-146a induction in a NF-κB-dependent 
manner by Epstein-Barr virus Latent Membrane Protein 1 (LMP1) in human B lymphocytes 24. Study 
from miR-146a-deficient mice suggested that B cells in these mice are also hyper-activated and 
autoreactive, because we can detect anti-dsDNA antibodies in the serum and a small percentage of B-
cell lymphomas in aging miR-146a-/- mice 19,44. We have also seen de-repression of TRAF6 and 
IRAK1 by Western blot in splenic B cells from miR-146a-/- mice 19. Further studies will be required to 
understand the function of miR-146a in B cells.  
 
Functions of miR-146a in Hematopoiesis 
In addition to the functional role of miR-146a within immune cells, miR-146a also is important for 
regulating the development of hematopoietic cells (Figure ii). Consistent with its expression pattern, 
miR-146a plays a role in the development of a wide spectrum of hematopoietic cells. An early in vitro 
study using human leukemic cell lines and CD34+ progenitor cell culture suggested a role for miR-
146a in megakaryopoiesis, during which upregulation of the transcription factor PLZF represses miR-
146a expression, which in turn leads to increased expression of a direct target of miR-146a, CXCR4. 
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In this study, overexpression of miR-146a led to impaired megakaryocytic proliferation, differentiation 
and maturation 27. However, the cell-autonomous regulation of miR-146a in megakaryopoiesis is 
challenged by a later study, which showed no detectable changes in megakaryocyte development and 
platelet activation properties by overexpression of miR-146a in all hematopoietic cells in mice 45. This 
discrepancy may be a consequence of differences between the two experimental systems, an in vitro 
study with human cells versus a mouse in vivo system. Nevertheless, the study done with an 
overexpression system does not exclude a role for miR-146a in megakaryopoiesis because miR-146a 
expression is upregulated during megakaryopoiesis and the endogenous level of miR-146a may be 
sufficient to downregulate the relevant target genes to ensure normal megakaryocyte development. On 
the other hand, knocking down miR-146a and miR-145 concurrently with a “sponge” in mouse 
hematopoietic stem and progenitor cells (HSPCs) leads to megakaryocyte expansion and 
thrombocytosis in vivo. However, this effect may be indirectly mediated by increased production of 
the positive acting cytokine IL-6 from miR-146a-deficient myeloid and lymphoid cells 37. In contrast, 
significant reduction in platelet counts is frequently seen in aging, but not in young, miR-146-/- mice 
19,44. The observed thrombocytopenia in aging miR-146a-/- is a manifestation of bone marrow failure 
and fibrosis or chronic dysregulation of inflammatory cytokine production. Overall, miR-146a has a 
regulatory function in megakaryopoiesis in a cell-intrinsic manner and/or by controlling the 
inflammatory environment. The involvement of miR-146a in myeloid development is particularly 
interesting. Stable knock-down of both miR-145 and miR-146a concurrently in mouse HSPCs results 
in variable neutropenia and decreased colony-forming ability of bone marrow cells 37. In support of 
miR-146a as the dominant miRNA in this effect, over-expression of TRAF6, a validated target of miR-
146a, also leads to mild neutropenia, with a subset of mice progressing to marrow failure or acute 
myeloid leukemia 37. More conclusive data came from the subsequent analysis of miR-146a-/- mice. 
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MiR-146a-/- mice are born at the expected Mendalian frequency and show no detectable phenotype 
during the first 2 months of their life in the absence of an inflammatory or infectious challenge. This 
suggests that miR-146a is not an essential gene for the proper development of blood lineages under 
steady state in young mice. However, with natural aging, miR-146a-/- mice develop a progressive 
myeloproliferative phenotype in both spleen and bone marrow. Specifically, there is a significant 
increase in the percentage of CD11b+ cells in their spleens and bone marrows. It can readily be 
detected by FACS analysis of 6-month-old miR-146a-/- mice. The myeloid expansion becomes 
progressively larger by 12 months, as indicated by more than a 3-fold increase in the CD11b+ 
percentage and more than a 10-fold increase in the total number of CD11b+ cells in spleens. Bone 
marrows of these mice are also dominated by myeloid cells, representing close to 80% of all bone 
marrow cells 19,44. Bone marrow-derived macrophages (BMDM) developed from young knockout 
mice also proliferate faster in response to macrophage colony-stimulating factor (M-CSF). Consistent 
with this observation, increased surface expression of CSF1R, the receptor for M-CSF, is also detected 
in the knockout spleen, bone marrow and peripheral blood myeloid cells 19,44. In addition, miR-146a-
deficiency also confers a proliferative advantage on Ly-6Chi monocytes in bone marrow, spleen and 
the peritoneal cavity in inflammatory conditions 17. Mechanistically, miR-146a-/- spleen and bone 
marrow cells exhibit increased transcription of NF-κB-responsive genes. Increased NF-κB p65 
translocation to the nucleus is also evident in miR-146a-/- spleen cells. The increased 
myeloproliferation is dependent on the activation of NF-κB because genetic ablation of an important 
subunit of NF-κB, p50, suppresses myeloproliferation 44. Study pursuing the mechanism of NF-κB-
driven myeloproliferation will help shed further insight on the molecular link between chronic 
inflammation and hematopoietic malignancy. Enforced expression of miR-146a in bone marrow 
transplant studies in mice has produced inconsistent results. One study reported that overexpression of 
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miR-146a in 5-fluorouracil (5-FU) treated bone marrow cells results in a transient myeloid expansion 
that subsequently returns to normal 21. Another report showed no detectable change in circulating 
granulocytes, T cells and B cells by overexpressing miR-146a in lineage negative bone marrow cells 
45. Lastly, one other group showed that ectopic expression of miR-146a in sorted LKS (Lineage-
cKit+Sca1+) cells directs the selective differentiation of HSCs into peritoneal macrophages in mice. 
Surprisingly, other than the peritoneal cavity, this study failed to detect any transplanted miR-146a-
expressing donor cells in the peripheral blood, spleen and bone marrow, precluding comparison in 
these hematopoietic compartments with the other overexpression studies. The same report also showed 
that inhibition of miR-146a impairs macrophage formation during early zebrafish development 25. In 
addition to different investigators overexpressing miR-146a in different fractions of bone marrow cells, 
it is also unclear whether the levels of miR-146a overexpression achieved were comparable between 
these studies. Despite some inconsistent findings, it appears that enforced expression of miR-146a in 
mouse bone marrow cells has an overall minor effect on hematopoiesis, at least in the major 
hematopoietic organs under steady state.   
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Figure ii. A simplified schematic depiction of hematopoietic tree highlighting the role of miR-146a in 
hematopoiesis and immune cell function. A. miR-146a negatively regulates myelopoiesis and 
myeloproliferation during inflammation and aging. In the absence of miR-146a, increased 
myeloprolifreation is observed. B. miR-146a negatively regulates megakaryopoiesis. Overexpression 
of miR-146a inhibits megakaryocyte proliferation and differentiation while down-regulation of miR-
146a promotes megakaryocyte expansion and platelet production. However, in aging miR-146a-
deficient mice with bone marrow fibrosis, thrombocytopenia is observed. MiR-146a is a negative 
regulator of monocyte and macrophage activation (C) and effector T cell activation (D). E. In 
regulatory T cells, miR-146a positively controls Treg functional competence. In the absence of miR-
146a, Treg cells are defective in suppressing effector T cell activation.    
 
Overview of MiRNA-146a in Pathology    
The importance of miR-146a is further exemplified by its extensive involvement in immunological 
pathologies, including autoimmunity and hematologic malignancy. Loss-of-function studies in mice 
have provided some important insight in the role of miR-146a in the pathogenesis of autoimmunity. 
Genetic deletion of miR-146a in all the cells in mice leads to autoimmunity, indicated by 
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splenomegaly, lymphadenopathy, lymphocyte-infiltration in liver, kidney and lung, and the 
development anti-dsDNA antibodies 19. The contribution of miR-146a to autoimmunity occurs in at 
least 3 separate ways: (1) regulation of miR-146a in effector T cells; (2) regulation of miR-146a in 
Treg cells; (3) regulation of myeloid cell-mediated inflammation. MiR-146a-deficient T effector cells 
contribute to autoimmunity in a cell-intrinsic manner. MiR-146a-deficeint T cells remain hyper-
responsive to antigen stimulation when adoptively transferred into wild type mice and they induce a 
spontaneous autoimmune pathology when transferred into Rag1-/- mice. Mechanistically, the 
enhanced proliferation, impaired activation-induced apoptosis, and exaggerated effector cytokine 
production seen in miR-146a-deficient CD4 and CD8 T cells derive from uncontrolled NF-κB 
activation as a result of de-repressed TRAF6 and IRAK1 20. Whether the multi-organ autoimmune 
pathology is caused by a general over-activation of miR-146a-deficient T cells or by a more specific 
autoreactivity against a particular cell type or self-antigen remains an interesting unanswered question. 
In addition, miR-146a-deficient Treg cells are also functionally defective in suppressing excessive Th1 
response. In the absence of miR-146a, upregulation of STAT1 in Treg cells is responsible for the 
failure to suppress wildtype effector T cells, leading to fatal IFNγ-mediated autoimmunity in a variety 
of organs 43. The chronic inflammatory environment conditioned by miR-146a-deficient myeloid cells 
also contributes to autoimmune pathology by further stimulating T-cell and promoting tissue damage 
19,44. Lastly, anti-dsDNA antibodies are present in the serum of aging miR-146a-/- mice 19. Future 
studies examining of the role of miR-146a in B cells may yield additional insight into the regulation of 
autoantibody production. Given the widespread expression of miR-146a outside of hematopoietic 
cells, miR-146a may exert protective function in non-hematopoietic tissues. Evidence supporting this 
comes from studies on lung epithelial cells and neonate guts 46-47. Interestingly, during the dramatic 
transition from a sterile environment to a bacteria-colonized surface in neonate guts, sustained miR-
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146a expression seems to be critical to mediate innate immune tolerance by repressing IRAK1 46. In 
light of this, we speculate that miR-146a-deficiency in intestinal epithelial cells may lead to intestinal 
inflammation, contributing to the overall autoimmune pathology in miR-146a-/- mice. Corroborating 
the in vivo studies in mice, miR-146a has been found to be extensively dysregulated in human patients 
with autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA). In lupus patients, miR-146a expression is downregulated in peripheral blood mononuclear cells 
(PBMCs). In addition, the level of miR-146a expression is negatively correlated with disease severity, 
with lower expression correlating with more active disease and proteinuria symptoms 42. Type I IFN is 
suggested to be the responsible pathway upregulated in lupus and additional targets of miR-146a, IRF5 
and STAT1, have been identified based on 3’UTR luciferase reporter assay and Western blot analysis 
in 293T cells overexpressiing miR-146a. Interestingly, enforced expression of miR-146a in PBMCs of 
lupus patients can downregulate a subset of IFN-responsive genes 42. Additional evidence comes from 
genome-wide association studies that identified SNPs (single-nucleotide polymorphism) in the 
regulatory region of miR-146a that are associated with lupus disease risk 48-49. One such SNP 
(rs57095329) in the promoter region of miR-146a is associated with the binding strength of 
transcription factor Ets-1, another lupus-susceptibility gene. The risk-associated G allele in this SNP 
correlates with reduced Ets-1 binding and decreased miR-146a expression 49. In contrast to SLE where 
miR-146a expression is shown to be down-regulated, over-expression of miR-146a is frequently 
detected in rheumatoid arthritis (RA) patients 50-52. MiR-146a also seems to be highly expressed in 
osteoarthritis cartilage 53. Despite that both SLE and RA are autoimmune diseases with some shared 
characteristics, the underlying etiologies may be distinct. For example, chronic inflammation is a 
shared pathology, but the dysregulated cytokine profiles are different between SLE and RA. The IFN 
pathway is intimately linked to the pathogenesis of SLE while increased TNFα, IL-1β, and IL-6 
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production are more prominent features of RA 50. Because pro-inflammatory cytokines can 
significantly upregulate miR-146a expression in various cell types, increased miR-146a expression 
may simply reflect the hyper-inflammatory environment and may be a useful marker for disease 
severity in RA. On the other hand, miR-146a-deficiency may be causally related to the pathogenesis of 
SLE. It will be interesting to further investigate the involvement of miR-146a-deficiency in the 
development and progression of SLE and a number of other autoimmune diseases and whether 
upregulation of miR-146a may have therapeutic benefit in mouse models and human clinical samples. 
In the addition to the role of miR-146a in Th1 cells, Treg cells and monocyte/macrophages, 
understanding the function of miR-146a in T17 cells 54, a key cell type in a number of autoimmune 
diseases, may provide additional insight on this miRNA’s involvement in autoimmunity. There is also 
some evidence suggesting a role of miR-146a in atherosclerosis, a less studied aspect of miR-146a 
biology. Two reports suggested that upregulation of miR-146a may inhibit atherosclerosis by 
suppressing TLR-4 and CD40L expression in low-density lipoprotein (LDL)-induced macrophages 
and dendritic cells 55-56.   
 
MiRNA-146a in Hematologic Malignancy    
Recent studies have also revealed an important role of miR-146a in hematologic pre-malignancy and 
malignancy, most notably myelodysplastic syndromes (MDS), myeloproliferative disease, myeloid 
cancer and bone marrow failure. MDS represent a heterogeneous group of clonal diseases of HSC 
origin characterized by ineffective hematopoietic differentiation, peripheral blood cytopenias, bone 
marrow dysplasia, and a propensity to progress to leukemia and bone marrow failure. Recent studies 
have made significant advances on the molecular pathogenesis of MDS, including dysregulated 
expression of miRNAs 57-58. Starczynowski et al have shown that two miRNAs, miR-145 and miR-
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146a, are located in or near the commonly deleted region of 5q- syndrome, a common subtype of MDS 
37. Accordingly, expression of these two miRNAs is reduced in patients of 5q- syndrome. The same 
study also showed that the stable knockdown of miR-145 and miR-146a concurrently in mouse HSPCs 
recapitulates many of the key features of human 5q- syndrome, including thrombocytosis, 
megakaryocytic dysplasia and mild neutropenia. In addition, overexpression of TRAF6, a target of 
miR-146a, was sufficient to phenocopy many of the features of knocking down miR-145 and miR-
146a, suggesting that miR-146a may be a more dominant miRNA. Studies with miR-146a knockout 
mouse are reaffirming. With increasing age, miR-146a-/- mice develop myeloid expansion in spleen 
and bone marrow, pancytopenia in the periphery and a propensity to progress to bone marrow failure 
and myeloid cancer, a constellation of features reminiscent of a mixed myelodysplastic syndrome and 
myeloproliferative neoplasm (MDS/MPN) 19,44. Mechanistically, increased NF-κB activation is a main 
driver of the myeloproliferative and bone marrow failure phenotype because ablation of the p50 
subunit greatly reduces MDS/MPN symptoms. It is now increasingly appreciated that a distinct 
hematopoietic developmental program, termed inflammatory hematopoiesis, is activated in bone 
marrow during inflammation to promote myelopoiesis at the expense of lymphopoiesis and 
erythropoiesis 59. We speculate that uncontrolled and persistent inflammatory hematopoiesis may 
promote pathological features of MDS and MPN, and over time, the pathologic hematopoietic program 
becomes permanent and irreversible through additional genetic mutations and/or epigenetic changes. 
Because chronic inflammation is a prominent feature of miR-146a-/- mice during stimulation and 
aging, it will be interesting to investigate whether miR-146a may serve as a molecular link between 
chronic inflammation and hematopoietic malignancy, such as MDS and MPN. In addition to myeloid 
cancers, about 15% of miR-146a-/- mice also develop B-cell or mixed B and T-cell lymphomas by 18 
to 24 months 44. It’s not clear whether the mechanism underlying lymphoma development in miR-
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146a-deficient mice is distinct from the one driving myeloid oncogenesis. Many groups have 
extensively profiled miRNA expression in human leukemia in an effort to identify microRNA 
signatures associated with leukemia diagnosis, prognosis, and pathogenesis. Reports from different 
groups have identified miR-146a downregulation in CD34+ cells or total bone marrow cells from 
patients with 5q- syndrome 37,58,60. However, miR-146a downregulation is not consistently observed in 
leukemia studies. One expression profiling study showed that miR-146a is downregulated in bone 
marrow cells of AML patients compared to normal CD34+ cells 61. However, in another study that 
compared miRNA expression between AML and ALL samples, increased expression of miR-146a in 
both ALL and AML was shown to correlate with poor survival 62. MiR-146a was also shown to 
function as a tumor-suppressor in natural killer/T cell lymphoma and reduced expression of miR-146a 
was identified as a poor prognostic factor 63. It seems miR-146a-downregulation is a consistent feature 
of 5q- syndrome or even all MDS and may be involved in the pathogenesis of MDS. The role of miR-
146a in leukemia and lymphoma requires further clarification.  
 
Relationship between MiR-146a and MiR-155 
MicroRNA-155 (miR-155) is another miRNAs identified from our original screen for miRNAs 
induced upon NF-κB activation 16. However, in contrast to miR-146a, miR-155 plays an almost exact 
opposite role in immunity and hematopoiesis. For more detailed reviews of miR-155 biology, we refer 
you to these recent reviews elsewhere 3,36,59,64-65. Here we will only focus on the aspect of miR-155 
function opposing that of miR-146a. NF-κB activates an elaborate and potent transcription program 
central to inflammation and immunity. Because of the potency of this pathway, proper regulation of 
the magnitude and duration of NF-κB activation is essential 36,66-68. NF-κB-induced miRNAs, miR-
146a and miR-155, may be two important regulators that balance the negative and positive effects 
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driven by NF-κB activation. The opposing roles of miR-146a and miR-155 have been most clearly 
demonstrated in the function and development of myeloid cells. While basal expression of miR-155 is 
low in myeloid cells, many of the inflammatory stimuli that can induce miR-146a expression, 
including TLR ligands and pro-inflammatory cytokines, also upregulate miR-155 expression 
significantly 15,69. In regulating the functional capacity of myeloid cells, upon induction miR-155 
promotes expression of pro-inflammatory cytokines and the IFN response. This regulation is most 
likely through repression of SOCS1 and SHIP1, both negative regulators of the pro-inflammatory 
pathways 70-71. Consistent with this, inhibition of miR-155 in macrophages confers tolerance to 
endotoxin shock in mice while mice with miR-155 overexpression become hypersensitive 71-72. The 
exactly opposite effect has been observed with miR-146a inhibition and overexpression 19. In addition 
to pro-inflammatory cytokine production, miR-146a and miR-155 also regulate immunity in the 
opposite manner. In general, mice with targeted miR-155 deletion are immuno-compromised as 
indicated by attenuated immune response to immunization and infection 73-74. On the other hand, 
inhibiting miR-146a may result in a heightened immune response as shown by enhanced protection 
against Listeria infection 17. MiR-146a and miR-155 also have an opposite effect in regulating certain 
aspects of T cell function. As discussed above, miR-146a-deficient CD4 T cells display a hyper-
activated response upon TCR stimulation while miR-155-deficient CD4 T cells are attenuated in IL-2 
and IFNγ cytokine production upon TCR stimulation 20,73. Similarly, miR-155 and miR-146a also 
function in an opposite direction in autoimmunity. Contrary to miR-146a-/- mice that are prone to 
developing autoimmune disease, miR-155-/- mice were shown to be significantly resistant to an 
induced model of experimental autoimmune encephalomyelitis (EAE) because of a deficit in 
inflammatory T-cell development and, to a lesser extent, a defect in myeloid dendritic cell function 75. 
In a recent effort to directly study the opposing function of miR-146a and miR-155, mice deficient of 
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miR-146a, miR-155, or both miRNAs were implanted with subcutaneous solid tumors and were 
shown to have differential ability to control tumor growth 76. This study showed again that in the 
context of antitumor immunity, miR-146a and miR-155 play opposing roles with miR-155 promotes, 
while miR-146a represses antitumor immunity, correlating their functions to regulate IFNγ-producing 
CD4+ T cells development. As described above, miR-146a and miR-155 are concurrently up-regulated 
in response to pro-inflammatory cues. Data suggest that miR-146a and miR-155 may counterbalance 
each other during inflammatory hematopoiesis. Sustained expression of miR-155 in mouse HSPCs 
results in a myeloproliferative disorder, characterized by profound myeloproliferation with dysplastic 
changes in the bone marrow, splenomegaly as a result of extramedullary hematopoiesis, peripheral 
anemia, lymphopenia, and thrombocytopenia with increased myeloid cells 15. The constellation of 
hematologic abnormalities seen in miR-155-overexpressing mice is strikingly similar to the one 
observed in aging miR-146a-deficient mice 44. MiR-155-induced myeloproliferative disorder is 
thought to be primarily through repressing SHIP1 70. In addition, over-expression of miR-155 in a B-
cell-specific manner in a transgenic mouse model with E(mu)-promoter-driven miR-155 expression 
results in B-cell leukemia and lymphoma 77. Similar B-cell lymphoma pathology has also been 
observed in a subset of aging miR-146a-/- mice 44. Given the above evidence, it is tempting to 
speculate that miR-146a and miR-155 are evolutionarily selected to function in a tug-of-war manner to 
properly control the magnitude and duration of NF-κB activation. Balanced level and proper timing of 
miR-146a and miR-155 expression represents one critical layer of regulation to ensure that NF-κB is 
activated in a controlled manner.    
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CHAPTER ONE 
NF-κB Dysregulation in MicroRNA-146a-deficient Mice Drives the Development 
of Myeloid Malignancies 
 
INTRODUCTION 
MicroRNAs (miRNA) are a group of ~19-23 nucleotide-long non-coding RNAs that repress target 
gene expression by a combination of mRNA degradation and translation inhibition 8. Recent studies 
have revealed important physiological roles of miRNAs in many aspects of mammalian hematopoiesis 
and immune cell function, and their altered expression has been linked to pathological conditions of 
the immune system, such as hematologic cancers and autoimmunity 3,78-79.  
 Chronic inflammation contributes to cancer initiation and progression. Among a myriad of proposed 
mechanisms linking inflammation to cancer, NF-κB has been identified as a key mediator of 
inflammation-induced carcinogenesis 80. Moreover, constitutive NF-κB activation is frequently 
detected in many types of lymphoid and myeloid malignancies 81-82. Hence understanding how NF-κB 
activity is downregulated has been a focus of study with important advances in recent years 67.  In 
particular, NF-κB regulation by non-coding RNAs has recently begun to be characterized. A few years 
ago, we carried out a microarray screen to identify miRNAs induced by NF-κB activation and miR-
146a was discovered to be one of the miRNAs induced by lipopolysacharide (LPS) in a human 
monocytic cell line. The induction of miR-146a was shown to be NF-κB-dependent, and upon 
induction, miR-146a functioned to directly down-regulate TNF receptor-associated factor 6 (TRAF6) 
and Interleukin-1 receptor-associated kinase 1 (IRAK1), two of the signal transducers in the NF-κB 
activation pathway 16. Based on this study and others 22,83, we hypothesized that miR-146a, by 
repressing TRAF6 and IRAK1, may have an effect on NF-κB activation, dampening and/or 
 21
terminating an inflammatory response via a negative feedback loop. To definitively characterize the 
function of miR-146a in vivo and directly test the hypothesis that miR-146a is a negative regulator of 
the NF-κB pathway, we generated two independent mouse strains with a targeted germline deletion of 
miR-146a, one on the mixed C57BL/6x129/sv background and one on the pure C57BL/6 background. 
Initial study done primarily with the mixed background miR-146a-/- mice showed that miR-146a-/- 
mice were hypersensitive to LPS challenge, and aging miR-146a-/- mice developed autoimmune-like 
disease, myeloid proliferation in their spleens, and hematopoietic tumors 84. However, the cellular 
lineage of the tumors and the mechanistic basis of miR-146a-deficiency mediated myeloproliferation 
remained important unanswered questions. In addition, the relationship of the tumor phenotype in 
miR-146a-/- mice and NF-κB dysregulation was uncertain due to the multiple potential targets of miR-
146a in different molecular pathways. Here, we focus on characterizing the incidence, cellular lineage, 
and transplantability of the tumors and to understand the molecular basis of oncogenesis.  
We have found that when they are allowed to age naturally, miR-146a-/- mice on a pure 
C57BL/6 background develop a chronic inflammatory phenotype with progressive myeloproliferation 
involving both the spleen and the bone marrow, which eventually progresses to splenic myeloid 
sarcoma and bone marrow failure at about 18 months of age. Lymphomas of either a B-cell lineage or 
a mixed T-and-B-cell lineage are also observed in older miR-146a-/- mice at a much higher frequency 
than in wild-type animals. Myeloproliferation in miR-146a-deficient mice are driven primarily by the 
action of NF-κB because reduction in the NF-κB level by deletion of the NF-κB subunit p50 
effectively suppresses the pathology. Thus, we have provided genetic evidence that miR-146a 
functions as a tumor suppressor in both myeloid and lymphoid cells and that chronic NF-κB activation 
as a result of miR-146a-deficiency is responsible for driving the myeloproliferative disease, which can 
progress to malignant myeloid sarcoma.  
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RESULTS 
miR-146a knockout mice develop myeloid and lymphoid malignancies.  
The miR-146a-deficient pure C57BL/6 mouse was made by deleting about 300 base pairs of genomic 
DNA fragment containing the miR-146a  precursor 84. The miR-146a-deficient mice (homozygous 
knockouts, designated as miR-146a KO) were born at the expected Mendelian frequency and appeared 
to be normal at birth. But starting at about 5-6 month of age, they developed progressively enlarged 
spleens. By 18-22 months of age, 80% of the KO mice were moribund and were culled for analysis. 
However, the entire cohort of age-matched littermate C57BL/6 (WT) control mice, except for one case 
of thymoma and one case of seizure, were still alive and healthy (Figure S1A). On necropsy, KO mice 
demonstrated various degrees of splenomegaly, with KO spleens on average weighing 6-7 times more 
than WT spleens (Figure S1B and S1C). By FACS analysis, splenomegaly was correlated with a 
massive expansion of the CD11b+ myeloid population (Figure S1D, S1E, and S1F). Expanded splenic 
hematopoiesis was also noted based on the increased Ter119+ erythroid precursor population in the 
spleen. About 40% of the mice demonstrated distinct splenic tumors (Figure 1A and 1B). The majority 
of these tumors displayed the histologic appearance of a myeloid sarcoma (Figure 1B) 85. FACS 
analysis of carefully dissected tumors showed that the cells derived from these tumors expressed the 
pan-myeloid antigen, CD11b (Figure 1B). Occasionally, liver and kidney were also heavily infiltrated 
by myeloid sarcoma (Figure S2A and S2B). A general role of miR-146a as a tumor-suppressor 
miRNA in the hematolymphoid system was demonstrated by the development of lymphomas of a B-
cell or a mixed T-and-B cell lineage in cervical lymph node, gastrointestinal tract, liver, and kidney, in 
about 20% of the KO mice (Figure 1A). Similar lymphoid tumors were not identified in wild-type 
mice. The lineage of these tumors was confirmed by FACS as well as immunohistochemical stains 
(Figure 1C and 1D and Figure S2C, and S2D). Histological analysis revealed that the lymphomas 
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ranged from low-grade follicular lymphoma (Figure S2C) to high-grade diffuse large B-cell lymphoma 
with apoptotic bodies and atypical mitosis (Figure 1C and Figure S2D).  
 
Myeloid tumors are transplantable into immunocompromised recipient mice.  
The ability of a mass of cells to form tumors upon transplantation to a secondary mouse can 
distinguish a malignant growth from a reactive inflammatory process. KO splenic tumor cells dissected 
from the tumor nodules in the spleen and wild-type (WT) control spleen cells were transplanted into 
immunocompromised Rag2-/-γC-/- Balb/c recipient mice intravenously (i.v.), with or without 
transduction by a retrovirus expressing enhanced green fluorescence protein (eGFP) and luciferase 
protein. For experiments with retroviral transduction, bioluminescent imaging was utilized as a 
sensitive method to track luciferase expression by the transplanted cells in vivo in recipient mice. 
Starting one to two weeks after intravenous injection, KO splenocytes showed markedly increased 
proliferation compared to wild-type splenocytes in recipient mice (Figure 2A). When whole body 
bioluminiscence intensity was quantified over the course of eight weeks, mice receiving KO 
splenocytes showed a progressive increase in signal culminating in an approximately 10-20-fold higher 
signal, indicating a proliferation of the transplanted cells, while WT cells did not (Fig 2B). 
Interestingly, recipient spleens, kidneys, and livers showed the strongest biolumniscence signal, 
indicating the proclivity of transplanted splenic tumor cells to localize to the same organs where the 
most significant myeloid tumor pathology was observed in the original KO mice. By two months 
following transplantation, most KO recipient mice became cachectic and moribund, while WT 
recipient mice showed some mild weight loss. In mice receiving KO spleen cells, but not in those 
receiving WT spleen cells, necropsy revealed significant myeloid pathologies, including enlarged 
spleens and massive infiltration of kidneys and livers by neoplastic myeloid cells (Figure 2C to F). 
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Interestingly, not every KO spleen was transplantable. Transplantation of age-matched KO splenocytes 
from mice without overt myeloid sarcoma did not result in significant myeloid pathology in recipient 
mice, suggesting there is a qualitative difference (e.g. additional mutations) between KO spleens with 
myeloproliferation and those with overt myeloid sarcoma.  
 
Chronic myeloproliferation and myelofibrosis in miR-146a deficient bone marrow.  
In addition to splenic myeloproliferation and/or myeloid sarcoma, the bone marrow of miR-146a KO 
mice showed significant myeloproliferative disease. By 18-22 months of age, the CD11b+ population 
accounted for 80% of all nucleated bone marrow cells, while the percentages of CD19+ B cell dropped 
to below 10% in miR-146a KO mice (Figure 3A and 3B). In line with the myeloid-dominated bone 
marrow, peripheral blood showed significant lymphopenia, anemia, and thrombocytopenia, but 
preserved granulocyte numbers (Figure 3C and S3A). In addition, the expanded CD11b+ population in 
both bone marrow and spleen was also predominantly Gr1+. An increased expression of macrophage 
colony stimulating factor receptor (CSF1R) was also noted in the myeloid population in both spleen 
and peripheral blood (Figure S3B). By 18-22 months of age, WT bone marrow showed partial 
replacement of bone marrow cells by adipose tissue as a result of aging, while KO bone marrow 
showed end-stage fibrosis or a hypercellular bone marrow. The end-stage KO bone marrow was 
markedly pale by gross analysis, and histologic sections demonstrated paucicellular marrow with 
thickened bone and fibrosis (Figure 3D and S3C). This chronic myeloproliferation resembles in some 
ways human myeloproliferative diseases that result in an end stage of marrow fibrosis.  
 
Spleen and bone marrow cells from miR-146a-deficient mice show increased activation of NF-
κB-mediated transcription.  
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We and others have previously identified TRAF6 and IRAK1 as targets of miR-146a in various cell 
types, including monocytes and macrophages 16,22. Because TRAF6 and IRAK1 are signal transducers 
upstream of NF-κB activation, their de-repression in miR-146a deficient mice could result in increased 
activation of NF-κB. In fact, we have recently demonstrated that TRAF6 and IRAK1 are derepressed 
in miR-146a KO mice 84. Therefore, we investigated whether increased NF-κB activation might be a 
feature of the myeloproliferation and/or myeloid sarcoma in the miR-146a-deficient mice. We 
extracted RNA from total nucleated spleen cells and total nucleated bone marrow cells and examined 
RNA expression levels for some genes well-known to be NF-κB-responsive, including interleukin-6 
(IL-6), tumor-necrosis factor α (Tnfα), monocyte-chemotatic protein 1 (Mcp1), A20, and the NF-κB 
subunit p50 (Nfkb1). In the absence of ex vivo stimulation, KO splenocytes and bone marrow cells 
showed basally up-regulated expression of a subset of NF-κB-responsive genes compared to the WT 
control, suggesting the presence of constitutively activated NF-κB (Figure 4A and 4B). For some of 
the genes, such as Tnfα and Mcp1, the expression was even higher in tumor cells isolated from the KO 
spleen (Figure 4A). To exclude the possibility that a different cellular composition is responsible for 
the difference, especially in spleens where KO spleens showed a 3-fold increase in CD11b+ myeloid 
population, we purified the CD11b+ population from WT and KO spleens by magnetic bead labeled 
cell separation (MACS). When the enriched CD11b+ splenocyte population was subjected to the same 
gene expression analysis, NF-κB-activated genes, including Tnfα and Mcp1, were still up-regulated in 
the KO population compared to the WT control (Figure 4C). To further confirm the status of NF-κB 
activation, we assessed the level of nuclear translocation of the NF-κB subunit, RelA (p65), by western 
blot analysis of the nuclear protein extract from total nucleated splenocytes. KO splenocytes showed a 
1.5- to 2-fold higher level of nuclear p65 than WT splenocytes, confirming the activated status of NF-
κB (Figure 4D). It is important to note that not every KO spleen showed constitutively higher level of 
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nuclear p65 protein. Increased nuclear p65 correlated well with the presence of myeloid sarcoma 
(Figure S4), suggesting that the activation of the NF-κB becomes constitutive only when the KO 
spleen progresses from myeloproliferation to myeloid sarcoma.  
 
Reduction in the NF-κB level rescues the myeloproliferation in spleen and bone marrow.  
Both gene expression and nuclear protein analysis indicated that the KO spleen and bone marrow cells 
showed increased NF-κB activation. To investigate whether activated NF-κB is a causal factor in the 
observed myeloproliferation, we bred the miR-146a KO strain with an Nfkb1 (p50) KO strain to 
generate the double transgenic strain with homozygous deletion in both miR-146a and the p50 subunit. 
p50-/- mice show no developmental abnormality in the immune system and elsewhere but display 
defective B cell proliferation and specific antibody production. Cytokine production, including IL-6, 
TNFα, and IL-1α, from LPS-stimulated macrophage is also impaired 86-87. When we intercrossed 
double heterozygotes for the two knockout genes, the various genotypes were born at the expected 
Mendelian frequency (Figure S5A) and showed no overt abnormalities. Littermates from different 
genotype groups, miR-146a+/+ p50+/+ (WT), miR-146a-/- p50+/+ (miRKO), miR-146a-/- p50+/- 
(miRKO p50HET), and miR-146a-/- p50-/- (DKO), were aged to 6-7 month-old and then were 
sacrificed for analysis for the development of myeloproliferation in spleen and bone marrow. As 
expected, by 6-7 months of age, miR-146a KO mice started to develop splenomegaly and 
myeloproliferation. Importantly, splenomegaly and myeloproliferative disease were significantly 
reduced in the miR-146a-/- p50+/- group, with the exception of a few outliers. The rescue from the 
myeloproliferative phenotype was more consistent in the miR-146a-/- p50-/- double knockout (DKO) 
group, as indicated by the reduction in spleen weight and the lack of myeloid cell expansion in the 
spleen and bone marrow (Figure 5A and 5B). In contrast to the pale, fibrotic bone marrow observed in 
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miRKO femurs, the bone marrow in DKO mice was a vibrant red color, similar to what was observed 
routinely in WT mice (Figure S5B). In the spleens of DKO mice, there was also significant reduction 
in Ter119+ cells relative to miRKO mice, suggesting that expanded splenic hematopoiesis was also 
rescued by the deletion of p50 in DKO mice (Figure 5B). We conclude that activated NF-κB as a result 
of miR-146a deletion is the primary factor driving myeloproliferation in miR-146a-deficient mice, 
because reduction in the NF-κB level by deleting the NF-κB subunit p50 effectively rescues the 
myeloproliferative phenotype.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28
FIGURE 
 
Figure 1. miR-146a-deficient mice develop myeloid and lymphoid malignancies. Mice were18-22 month-old 
miR-146a-/- mice (KO) and sex and age-matched C57BL/6 control mice (WT). 
(A) Incidences of myeloid and lymphoid malignancies observed in WT (n=39) and KO (n=43) mice.  
(B) Photograph, FACS plot, and histological analysis of a representative myeloid tumor from a KO 
spleen. Panel 3 and 4, Hematoxylin and eosin (H&E) stained spleen section. Left scale bar, 100 microns; right 
scale bar, 40 microns. Arrows, mitotic figures.  
(C) Photograph, FACS plot, and histological analysis of a representative B-cell lymphoma from a KO 
gastrointestinal tract. Panel 3 and 5, Hematoxylin and eosin (H&E) stained tumor section; Panel 4: Positive 
immunohistochemical staining (IHC) for B220. L to R scale bars are 100 microns in Panel 3, 4 and 40 microns 
in Panel 5.  
(D) Photograph, FACS plot, and histological analysis of a representative mixed T-and-B-cell 
lymphoma from a KO liver. Panel 3,4, and 5, Hematoxylin and eosin (H&E) stained liver section; L to R, scale 
bars are 400 microns, 100 microns, 40 microns. Lym, Lymphoma; Liv, relatively uninvolved liver.   
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Figure 2. Myeloid sarcoma is transplantable into immunocompromised Rag2-/-γC-/- recipient mice, causing 
lethal myeloid pathology. WT designates Rag2-/-γC-/- mice transplanted with WT splenocytes; KO designates 
Rag2-/-γC-/- mice transplanted with miR-146a KO splenocytes. (n=4 for WT and n=4 for KO; data are 
representative of three independent experiments. Student t-test, * designates p < 0.05)  
(A) Representative bioluminiscence images of Rag2-/-γC-/- recipient mice splenic side view.  
(B) Quantification of whole body bioluminiscence intensity from splenic side view of one 
representative experiment. Vertical axis is in logarithmic scale. Transduction efficiency is determined by flow 
cytometric analysis of GFP+ cells prior to injection. The bioluminescence intensity is normalized to the 
percentage of initially transduced cells.  
(C) Spleen weight of Rag2-/-γC-/- recipient mice.  
(D) Photographs of spleens, kidneys, and livers from representative Rag2-/-γC-/- recipient mice.  
(E) Flow cytometric analysis of myeloid cells (defined as CD11b+) in representative recipient kidneys 
and livers. SSC, side scatter.  
(F) Histological analysis (H&E staining) of livers and kidneys from Rag2-/-γC-/- recipient mice. 
Arrows, myeloid tumor cells infiltrating recipient liver and kidney.  
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Figure 3. Chronic myeloproliferation and myelofibrosis occur in miR-146a-deficient bone marrow. Mice were 
18-22 month-old miR-146a-/- mice (KO) and sex and age-matched wild type control mice (WT). Data are 
shown as Mean +/- SEM. Each individual dot represents one individual mouse.  
(A) Flow cytometric analysis of nucleated bone marrow cells from one representative WT mouse and 
one representative KO mouse for B cells (defined as CD19+) and myeloid cells (defined as CD11b+).  
(B) Percentage of B cells (defined as CD19+) and myeloid cells (defined as CD11b+) in nucleated bone 
marrow cells by flow cytometric analysis (n=12 for WT and n=17 for KO from at least three independent 
experiments).   
(C) Absolute numbers of total white blood cells, lymphocytes, red blood cells, and platelets by 
complete blood count (CBC) analysis (n=8 for WT and n=8 for KO).  
(D) Representative hematoxylin and eosin (H&E) stained tibia sections from KO mice showing 
myelofibrosis and WT control. WT: WT bone marrow; adi, adipose tissue. KO1: markedly hypercellular KO 
bone marrow that contains virtually no megakaryocytres (arrowhead, lower left panel) or erythroid islands 
(outlined by dashed line, lower left panel). KO2: fibrotic KO bone marrow; arrows in the upper right panel, a 
broad band of fibrosis, of which there are many in this field; within the dotted line, an area of new bone 
formation that may represent end-stage fibrosis; the lower right panel, the interface between an area of fibrosis 
(fib) with entrapped myeloid cells and new bone formation (bone). Scale bars, top row, 200 microns; bottom 
row, 40 microns.  
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Figure 4. Spleen and bone marrow cells from miR-146a-deficient mice (KO) show increased activation of 
the NF-κB-mediated transcription. Mice were 18-22 month-old miR-146a-/- mice (KO) and sex and age-
matched wild type control mice (WT). Data are shown as Mean +/- SEM. n equals to the number of mice 
analyzed from at least two independent experiments. Student t-test, * designates p<0.05, *** designates 
p<0.005.  
(A) Gene expression analysis of NF-κB-responsive genes in WT (n=7) nucleated splenocytes, KO 
(n=13) nucleated splenocytes, and myeloid tumor cells (Tumor, n=7) isolated from KO spleen by gross 
dissection.   
(B) Gene expression analysis of NF-κB-responsive genes in WT (n=9) and KO (n=11) bone marrow 
cells.   
(C) Gene expression analysis of NF-κB-responsive genes in CD11b+ population purified with MACS 
beads (WT n=9 and KO n=6). 
(D) Western blot analysis of the nuclear protein extracts from WT or KO spleen. Data are 
representative of three independent experiments.  
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Figure 5. Reduction in the NF-κB level by deleting the p50 subunit of NF-κB effectively rescues the 
myeloproliferative phenotype in miR-146a-deficient mice. All mice were 6-7 month-old miR-146a+/+, p50+/+ 
(WT), miR-146a-/-, p50+/+ (miRKO), miR-146a-/-, p50+/- (miRKO p50HET), or miR-146a-/-, p50-/- (DKO) 
mice (n=17 for WT, n=24 miRKO, n=10 for miRKO p50HET, and n=9 for DKO. Data are shown as Mean +/- 
SEM from at least three independent experiments. Student t-test, * designates p<0.05, ** designates p<0.01, and 
*** designates p<0.005.)  
(A) Spleen weight of WT, miRKO, miRKO p50HET, and DKO mice.   
(B) Percentage of T cells (defined as CD3ε+), B cells (defined as CD19+, myeloid cells (defined as 
CD11b+), and erythroid cells (defined as Ter119+) in nucleated spleen and bone marrow cells from WT, 
miRKO, miRKO p50HET, and DKO mice by flow cytometric analysis. 
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Figure S1. miR-146a-deficient mice develop myeloproliferation in spleens. Mice were 18-22 month-old miR-
146a-/- mice (KO), miR-146a+/- mice (HET), and sex and age-matched C57BL/6 control mice (WT). Data are 
shown as Mean +/- SEM. Each individual dot represents one individual mouse. At least 3 independent 
experiments were performed.  
(A) Kaplan-Meier survival curve of aging miR-146a KO and WT mice starting at 1 year of age (n=39 
for WT and n=43 for KO).   
(B) Photographs of spleens isolated from KO and WT mice.  
(C) Weight of spleens isolated from KO, HET, and WT mice (n=26 for WT, n=5 for HET, and n=33 
for KO).  
(D) Flow cytometric analysis of nucleated splenocytes from one representative KO mouse and one 
representative WT mouse for T cells (defined as CD3ε+), B cells (defined as CD19+), myeloid cells (defined as 
CD11b+), and erythroid cells (defined as Ter119+).   
(E) Percentage of T cells, B cells, myeloid cells, and erythroid cells, as defined above, in nucleated 
splenocytes in KO and WT mice by flow cytometry (n=15 for WT and n=21 for KO from at least three 
independent experiments).  
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(F) Correlation between spleen weight and percentage CD11b+ cells in spleen from 18-22 month-old 
miR-146a-deficient mice (n=19).  
 
Figure S2. Additional examples of myeloid and lymphoid malignancies in miR-146a-deficient mice.  
(A) Photograph, FACS plot, and histological analysis of a representative myeloid tumor infiltrating a 
KO liver. Panel 3 and 4, Hematoxylin and eosin (H&E) stained liver section. Liv, residual liver, MS, myeloid 
sarcoma infiltration. Scale bar on Panel 3, 200 microns and on Panel 4, 40 microns. Arrows, apoptotic 
hepatocytes at the edge of the infiltrate. 
(B) Photograph, FACS plot, and histological analysis of a representative myeloid tumor infiltrating a 
KO kidney. Panel 3 and 4, Hematoxylin and eosin (H&E) stained kidney section. Kid, residual uninvolved 
kidney; MS, myeloid sarcoma infiltration. Scale bar on Panel 3, 200 microns and on Panel 4, 40 microns. 
Arrow, markedly atypical mitotic figure.   
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(C) Photograph, FACS plot, and histological analysis of a representative B-cell lymphoma from a KO 
cervical lymph node. Panel 3 and 5, Hematoxylin and eosin (H&E) stained spleen section; Panel 4: Positive 
immunohistochemical staining (IHC) for B220. Scale bars are 100 microns in Panel 3, 4 and 40 microns in 
Panel 5.  
(D) Photograph, FACS plot, and histological analysis of a representative mixed T-and-B-cell 
lymphoma from a KO gastrointestinal tract. Panel 3, 4, and 5, Hematoxylin and eosin (H&E) stained tumor 
section. Scale bars are 200 microns, 100 microns, 40 microns from left to right.  Arrow on Panel 4, apoptotic 
body (“starry sky appearance”), arrowhead on Panel 5, large immunoblastic cell (there are many more in this 
field); arrow on Panel 5, atypical mitotic figure. 
 
Figure S3. Cell count and flow cytometric analysis of peripheral blood, spleen, and bone marrow.  
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(A) Complete blood count (CBC) of peripheral blood from 18-22 month-old miR-146a-/- mice (KO, 
n=8) and sex and age-matched wild type control mice (WT, n=8). Data are shown as Mean +/- SEM. Each 
individual dot represents one individual mouse. n.s., not significant.  
(B) Percentage of CD11b/Gr1 double positive cells and CD11b/CSF1R double positive cells in spleen, 
bone marrow (BM), and peripheral blood (PB) of 18-22 month-old miR-146a-/- mice (KO) and sex and age-
matched wild type control mice (WT). Data are shown as Mean +/- SEM. Each individual dot represents one 
individual mouse. Total number of mice ranges from 6 to 11 from 3 independent experiments. n.s., not 
significant.  
(C) Photograph of representative tibias and fibulas isolated from WT or KO mice.  
 
 
Figure S4. Western blot analysis of the nuclear protein extracts from spleens of 18-22 month-old miR-146a-/- 
mice (KO) and sex and age-matched wild type control. KO (T), KO spleen with myeloid sarcoma; KO, KO 
spleen without myeloid sarcoma.   
 
 
 
Figure S5.  
(A) Number of offspring (n=173) produced from p50+/- miR-146a+/- double heterozygote intercross. 
(B) Photograph of tibias from WT, miRKO, miRKO p50HET, and DKO mice.  
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DISCUSSION 
These results and our previous paper 84 demonstrate that miR-146a plays an important role as a tumor 
suppressor miRNA in hematopoietic lineages because chronic miR-146a-deficiency in mice leads to 
myeloid sarcomas in spleens and lymphomas in various organs. miR-146a controls myeloproliferation 
in both the spleen and bone marrow compartments primarily through negatively regulating NF-κB. 
NF-κB is known to activate many genes involved in inflammation so that this study provides direct 
evidence correlating the chronic inflammation caused by activated NF-κB and the development of 
progressive myeloproliferative disease.   
Consistent with the initial observation of miR-146a KO mice on the mixed C57BL/6x129/sv genetic 
background 84, miR-146a KO mice on the pure C57BL/6 background developed  progressive 
myeloproliferation in their spleens, although the onset was delayed compared with the mixed 
background mice. miR-146a KO on the pure C57BL/6 background also developed significant 
myeloproliferative disease in the bone marrow, which was not observed in the mixed background 
strain. Moreover, miR-146a KO mice on the pure C57BL/6 background displayed less severe 
autoimmune-like disease but developed a higher incidence of tumor later on in life. All these indicate 
that the genetic background can significantly influence the phenotypic manifestation of deleting the 
miR-146a KO gene.  
It is interesting that miR-146a-deficient mice showed no obvious abnormality early on when 
left unchallenged but gradually developed myeloproliferation in both spleen and bone marrow 
compartments starting at about 5-6 months of age. Eventually, more than 50% of the mice developed 
myeloid sarcomas and lymphomas at about 18-22 months of age. miR-146a normally down-regulates 
TRAF6 and IRAK1, and in the miR-146a-deficient mice, derepression of these important signal 
transducers may increase signaling to the NF-κB pathway. It should be noted that overexpression of 
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TRAF6 or IRAK1 in the 293 human embryonic kidney cell line is able to activate NF-κB 88-89, 
suggesting a possibility of cell-intrinsic activation of NF-κB when TRAF6 or IRAK1 is overexpressed 
at a high level. However, this is unlikely to be the case in miR-146a KO mice. We believe that the NF-
κB activation in miR-146a KO mice likely involves external stimulation from other cells (autoimmune 
stimuli) or from environmental pathogens/commensal bacteria for TRAF6/IRAK1 to amplify the 
signal and that the mechanism of myeloproliferation and oncogenesis requires repeated episodes of 
activation of NF-κB due to external stimulation. In support of this notion, our previous paper reports 
an increased expression of both TRAF6 and IRAK1 at the protein level in bone marrow-derived 
macrophages (BMDM) from young miR-146a KO mice. But there was no difference in the serum 
levels of TNFα and IL-6 inflammatory cytokine between young WT and KO mice without LPS 
challenge 84. In addition, constitutive NF-κB activity detected by conventional biochemical methods 
was only consistently noted in spleens with overt myeloid sarcoma (Figure S4). Based on this 
evidence, we suggest that the activation of the NF-κB may only become constitutive and significant 
when KO spleens transition from the pre-malignant myeloproliferative state to malignant myeloid 
tumor. Given the long latency and the partial penetrance of the tumor phenotype, there are likely 
secondary mutations cooperating in the oncogenesis, either complementing the NF-κB activity or 
amplifying it, resulting in malignant tumors. It will be interesting to identify secondary mutations 
driving this progression and malignant transformation.     
NF-κB family transcription factors are homo-or heterodimers of 5 subunits, RelA (p65), Nfkb1 
(p50), Nfkb2 (p52), RelB, and c-Rel. Among them, p65 and p50 are thought to play an important role 
in the induction of many of the inflammatory genes 90. In addition, nfkb1ΔCT/ΔCT mice, with elevated 
p50 activity as a result of targeted deletion of the C-terminal ankyrin repeats, display phenotypes 
similar to those of miR-146a-/- mice, namely chronic inflammation with splenomegaly and enlarged 
 39
lymph nodes 91. Moreover, deletion of p50 is able to partially rescue IkBα-deficienct mice, which 
display constitutive NF-κB activation, increased granulopoiesis, and neonatal lethality 92. Given the 
importance of the p50 subunit to NF-κB-driven inflammation, we bred miR-146a-/- mice with p50-/- 
mice to investigate the role of NF-κB activation in the pathogenesis of myeloproliferation in miR-
146a-deficient mice. We showed that p50-deficiency effectively rescued myeloproliferation in miR-
146a-deficient mice. The rescue seen in miRKO p50HET mice was not consistent and complete, but 
merely a delay of symptoms, because by about one-year-old, mice in the mIRKO p50HET group 
started to show increased myeloid cells while the DKO mice continued to show consistent rescue of 
the myeloproliferative phenotype. The 50% increase in spleen weight and the marginal increase in 
CD11b+ and Ter119+ cells in the spleen of DKO mice, compared to WT (Figure 5B and 5C), suggest 
that the other pathways and factors other than p50 may also be involved. In addition, p50-deficiency 
may not rescue all the phenotypes in miR-146a KO mice, such as autoimmunity as a result of defective 
regulatory T-cells and/or activated effector T-cells, which has been shown to be due to a different 
pathway, the Signal Transducer and Activator of Transcription 1 (STAT1)/interferon pathway 43. 
Autoimmune inflammation may contribute to the modestly increased spleen weight in the DKO mice.   
Constitutive NF-κB activation is a well recognized phenomenon in lymphoid and plasma cell 
malignancies, but the status of NF-κB activation in myeloid malignancies is less well characterized. 
Some recent studies have demonstrated constitutive NF-κB activity in cells from high-risk MDS, some 
AML cases, and CML with blast crisis, suggesting that constitutive NF-κB activation may be 
associated with more advanced myeloid malignancies 81,93-94. In many of these cases, the mechanisms 
for constitutive NF-κB activation remain to be established. It is likely that some of these myeloid 
malignancies with intrinsic NF-κB activity may have down-regulated miR-146a expression. Indeed, 
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reduced miR-146a has been found in MDS with chromosome 5q deletion and a subset of AML cases 
37,61.  
Based on this work and the work of others, it seems apparent that miR-146a is an important 
component of immune cell gene regulation and that its main function is to negatively regulate NF-κB. 
We demonstrate pathologic states as a consequence of miR-146a deficiency, corroborating work from 
other groups showing deregulation of this miRNA in human diseases.  Further work is required to 
better understand the pathogenesis of miR-146a deficient diseases in humans and to develop methods 
to deliver miR-146a to immune cells in order to reduce NF-κB activation.    
 
EXPERIMENTAL PROCEDURES 
Mice  
For a description of the miR-146a-/- generation and genotyping, see Supplemental Information and 
reference 84. All experiments with miR-146a-/- and p50-/- 87 mice were approved by the institutional 
Animal Care and Use Committee (IACUC) of the California Institute of Technology.  
Survival and Tumor Incidence Study 
Survival and tumor incidence studies were done by following a cohort of about 40 miR-146a-/- and 40 
littermate wild-type control mice for up to 24 months. Mice were carefully monitored for the 
development of diseases and were sacrificed when visibly ill. Tumor diagnosis was based on a 
combination of gross examination, histological analysis, immunohistochemistry, and flow cytometric 
analysis.  
Quantitative RT-PCR 
Total RNA was extracted with Trizol reagent (Invitrogen) from total nucleated splenocytes, bone 
marrow cells, CD11b+ enriched splenocytes after RBC lysis (Biolegend). CD11b+ enriched 
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splenocytes were purified by CD11b antibody-conjugated MACS beads (Miltenyi Biotec) according to 
manufacturer’s instructions. Complementary DNA was synthesized using iScript cDNA synthesis kit 
(Bio-Rad) followed by SYBR Green-based quantitative PCR (Applied Biosystem) as previously 
described 15. Rpl32 level was used as the normalization.  
Western Blot Analysis  
Nuclear protein lysates were extracted using nuclear extraction kit (Sigma) according to 
manufacturer’s instruction. Antibodies against p65 (sc-8008 and sc-372), laminA/C (sc-20681), and 
HRP-conjugated secondary antibody (sc-2031 and sc-2004 all from Santa Cruz Biotechnology) were 
used for detection. 
Flow Cytometry  
Cells were harvested, homogenized, and RBC lysed with RBC lysis buffer (Biolegend). Fluorophore-
conjugated antibodies against CD3ε, CD11b, CD19, Ter119, Gr1 (all from Biolegend) and CSF1R 
(Ebioscience) were used for staining. Cells were analyzed on a FACSCalibur (BD Bioscience) 
machine and data analysis was performed with FloJo software (Tree Star).   
Tumor Transplantation Experiments  
Tumor was grossly dissected out from miR-146a-/- mice. 1 X 106 splenic tumor cells or equal number 
of wild-type splenocytes were injected into 8-12 week-old Rag2-/-γC-/- recipients via retro-orbital 
vein. For experiments with retro-viral transduction, MIG-Luc (MSCV-IRES-GFP vector expressing 
firefly luciferase) retroviruses were prepared and used to infect murine cells as previously described 95. 
Flow cytometry was used to quantify the percentage of infected cells (GFP+) prior to injection and 
bioluminescence imaging (Xenogen) was used to monitor in vivo cell growth in Rag2-/-γC-/- 
recipients weekly for up to 2 months. Bioluminescence intensity was quantified with Living Image® 
2.50.1 (Xenogen).  
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CHAPTER TWO  
MicroRNA-146a is a Critical Guardian of the Quality and Longevity of 
Hematopoietic Stem Cells 
 
INTRODUCTION 
Hematopoietic stem cells (HSCs) have the ability to self-renew and replenish the entire hematopoieic 
repertoire during the lifetime of an organism. Balanced self-renewal versus differentiation of HSCs is 
intricately regulated to ensure the long-term maintenance of HSCs and the hematopoietic system 96. 
Under stressed conditions, such as inflammation and infection, the balance is shifted in favor of 
hematpoietic stem and progenitor cell (HSPC) proliferation and differentiation to produce more mature 
immune cells 97. Following the discovery that HSCs express TLRs and may sense and respond to 
infection and inflammatory signals directly 98, there has been an increasingly appreciation of the role of 
pro-inflammatory cytokines and infection in the modulation of HSC activity. Numerous recent studies 
have shown that TLR activation or interferon stimulation leads to proliferation, skewed myeloid 
differentiation and impaired engraftment and self-renewal of HSCs 99-101. Since its discovery over 25 
years ago, NF-κB has been shown to be active in a wide variety of innate and adaptive immune cells as 
well as non-hematopoietic cells and to function as an essential player in orchestrating inflammation 
and immune cell functions 66. However, the function of NF-κB in HSCs remains relatively unexplored. 
Under stress-free conditions, NF-κB is not essential for HSC function, because mice genetically 
deleted for NF-κB subunits, such as NF-κB1 (known as p50) and c-Rel, have no apparent 
developmental abnormality in the hematopoietic system. Mice engrafted with p50-/- or c-Rel-/- HSCs or 
RelA-/- fetal HSCs also develop relatively normal immune system under stress-free conditions 102. On 
the other hand, mice with activated NF-κB signaling, as a consequence of deleting IκBα, A20 (as 
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known as TNFAIP3), or the inhibitory domain of NF-κB1 (p50) or NF-κB2 (p52), display severe 
inflammation, early lethality, and complex phenotypes, making studies of HSCs difficult to perform 
and interpret 86,103. In recent years, microRNAs (miRNAs) have emerged as a class of small non-
coding RNAs involved in the regulation of NF-κB 36. Among them, miR-146a has been shown to be a 
particularly important negative regulator of NF-κB by targeting two upstream signal transducers, 
TRAF6 and IRAK1. Mice with targeted miR-146a deletion represent one of the first genetic mouse 
models with NF-κB-driven chronic and low-grade inflammation that develops spontaneously with 
aging and can be accelerated by repeated stimulation, allowing investigation of the the long-term 
effects of chronic inflammation and NF-κB activation on HSCs and oncogenic processes 19,44. Given 
this background, we have used miR-146a-deficient mice to examine the function of NF-κB and miR-
146a in HSCs during chronic inflammation and to directly test a long-standing hypothesis that chronic 
inflammation promotes excessive HSC proliferation and differentiation and can lead to eventual HSC 
exhaustion and pathological myelopoiesis. Here we demonstrate that this single miRNA, miR-146a, 
functions as a critical regulator of HSC homeostasis during chronic inflammatory stress in mice. In the 
absence of miR-146a, HSC homeostasis is disrupted under physiological stresses such as aging and 
periodic bacterial encounters, as indicated by declines of HSC number and quality and accelerated 
HSC proliferation and differentiation. Chronically, these nominal stressors can lead to severe 
pathologies, such as HSC exhaustion, bone marrow failure and development of myeloproliferative 
disease, produced by chronic NF-κB hyperactivation and IL-6 overproduction. This study speaks to a 
molecular pathway involving miR-146a/TRAF6/NF-κB/IL-6 that links chronic inflammatory stresses 
to the functional decline and depletion of HSCs and the development of myeloproliferative diseases. 
 
 
 44
RESULTS 
MiR-146a regulates HSC numbers during chronic inflammatory stress 
To examine the role of miR-146a we first assessed the pattern of expression of it and its related family 
member, miR-146b, during hematopoietic differentiation. We purified by FACS various types of 
hematopoietic stem and progenitor cell (HSPC) populations from young wild type (WT) mice. We 
found that miR-146a and miR-146b were expressed at variable levels throughout hematopoietic 
development. The expression of miR-146a increased by 2-fold as long-term HSCs (defined as Lineage-
Sca1+cKit+ CD150+CD48-) differentiated into a mixed pool of short-term HSCs and multpotent 
progenitor cells (MPPs) (defined by Lineage-Sca1+cKit+, referred to as LSK cells). The lowest 
expression of miR-146a was detected in myeloid progenitor cells (defined by Lineage-Sca1-cKit+, 
referred to as L-S-K+ cells) (Fig. 1A). In comparison, miR-146b expression was more uniform 
throughout hematopoietic development (Fig. 1A). This expression pattern suggests that miR-146a and 
miR-146b could be functional in cells as primitive as the long-term HSCs and throughout 
hematopoietic development.  
To characterize the physiological function of miR-146a in HSCs, we examined the 
consequences of miR-146a deficiency on various hematopoietic cells using mice with a targeted 
deletion of the miR-146a gene 19,44. We found identical numbers of phenotypically defined subsets and 
equal colony-forming ability in vitro in WT and miR-146a-/- (miR-146a KO) 6-week-old mice (Fig. 
S1A-C). These data indicate that deleting miR-146a has no detectable effect on hematopoiesis early on 
in life in a standard pathogen-free environment.  
We have previously shown that miR-146a KO mice develop spontaneous inflammation as they 
age 19,44. To characterize the role of miR-146a in HSCs during chronic low level inflammation, we 
allowed age-and-sex-matched WT and miR-146a KO mice to age over a year. By 4 months, miR-146a 
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KO mice developed a mildly hypercellular bone marrow indicated by an increase in total bone marrow 
CD45+ cells, LSK cells and long-term HSCs, with unaltered percentages of CD19+, CD11b+ and 
CD3ε+ cells (Fig. S1D). However, the increase in bone marrow HSPCs and mature cells was not 
sustained. By 8 months of age, miR-146a KO mice showed a significant decrease in the number of 
total bone marrow cells and phenotypically defined HSPCs, including LSK cells and CD150+CD48- or 
EPCR+ long-term HSCs (Fig 1B, C). The depletion became progressively more severe by 12 months 
of age when the majority of miR-146a KO mice showed only a residual number of CD45+ bone 
marrow cells and nearly complete exhaustion of HSCs (Fig 1D). To understand the cellular process 
leading to a transient hypercellular marrow and eventual HSC exhaustion, we analyzed bone marrow 
and spleen of aging miR-146a KO mice. Accelerated hematopoietic differentiation from long-term 
HSCs to LSK cells and mature myeloid cells was evident in 8-month-old mice, as shown by an 
increased percent of LSK cells within the total bone marrow but a significantly decreased fraction of 
long-term HSCs among the LSK cells, (Fig 1E). By this age, miR-146a KO mice have already 
developed a prominent myeloproliferative phenotype in the spleen 44. In addition, miR-146a KO mice 
also showed a significant increase in the number of LSK cells and long-term HSCs in their spleens, 
suggesting either HSPC mobilization from bone marrow to spleen or de novo splenic HSPC 
proliferation in response to bone marrow failure (Fig. 1F). Thus, although miR-146a KO mice contain 
normal levels of HSPCs when they are young, as they age, they go through a hypercellular stage and 
then eventually start to lose bone marrow HSCs and differentiated cells, leading to HSC exhaustion 
and bone marrow failure. This is likely due to accelerated HSC differentiation into progenitor and 
mature cells, especially of the myeloid lineage. It is accompanied by an increased appearance of HSCs 
in the spleen, probably as a form of homeostatic compensation.  
 46
Importantly, we found that chronic inflammatory stimulation with bacterial components in 
young miR-146a KO mice was sufficient to accelerate the development of the same hematopoietic 
defects seen during aging of these mice. We stimulated 8-week-old WT and miR-146a KO mice with 
LPS repeatedly for a month and observed an accelerated differentiation of long-term HSCs towards 
LSK cells and myeloid cells in miR-146a KO mice, compared to WT mice, a phenotype similar to the 
one that spontaneously occurs during aging of the KO mice (Fig 1G-I and S1E). Thus, miR-146a is 
needed to maintain HSC homeostasis in response to chronic inflammation. This suggests that the stress 
of chronic inflammation may be the physiologically relevant stimulator of HSC deficiency and 
myeloproliferative disease in the miR-146a KO mice. Perhaps this becomes evident in aging miR-146a 
KO mice not subjected to experimental inflammatory stimulation because of a low level continual 
exposure to bacterial materials even in our relatively clean conditions of animal husbandry. Whether 
true pathogens or commensals might be the inducing agents will require further investigation.  
 
MiR-146a-defciency results in progressive decline in the quality of HSCs 
In addition to the progressive loss of phenotypically defined HSCs in aging miR-146a KO bone 
marrow, we found that the functional quality of HSCs deteriorates in mice lacking miR-146a. To 
assess HSC function, we compared WT and miR-146a KO bone marrow HSCs in their ability to 
generate the entire hematopoietic repertoire competitively in vivo. Total bone marrow cells from either 
6-week-old WT or miR-146a KO mice, both which were CD45.2+, were transplanted along with an 
equal number of CD45.1+ WT bone marrow cells, into lethally irradiated CD45.1+ WT recipient mice 
(Fig 2A). Six months after transplant, CD45.2+ and CD45.1+ cells in both the CD45.2 WT/CD45.1 WT 
and CD45.2 KO/CD45.1 WT mice contributed identical proportions of cells in nearly all mature 
hematopoietic lineages and HSPCs (Fig 2B). Furthermore, when we purified long-term HSCs (defined 
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by LSK CD150+CD48-) from WT or miR-146a KO bone marrow for competitive repopulation assay, 
we again observed a similar contribution of WT or miR-146a KO HSCs to total white blood cells and 
HSPCs 6-month post transplantation (Fig S2A). However, when we extended the experiment past 10 
months, we began to observe a decreased contribution of miR-146a KO cells to long-term HSCs and 
LSK cells, but no reduction in CD45+ cells, in the bone marrow of CD45.2 KO/CD45.1 WT mice (Fig 
2C-E). These data indicate that miR-146a-deficient long-term HSCs from young mice have an intrinsic 
functional defect, when competed against WT cells, for the generation of the hematopoietic repertoire 
in the WT environment; however, the intrinsic defect of miR-146a KO HSCs takes 10 months to 
become apparent in this transplant setting.   
To investigate how age affects the quality of miR-146a KO HSCs, we used 4-month-old, instead of 6-
week-old, miR-146a KO and WT mice for competitive repopulation assay. At 4 months of age, miR-
146a KO mice display a modestly hypercellular bone marrow and mildly increased phenotypically 
defined HSCs, but no disease phenotype (Fig S1D). Surprisingly, miR-146a KO cells were out-
competed by their WT counterparts as early as the first month after the transplant, and there was a 
steady decline in their percentage over a period of 6 months  (Fig 2G, H). Six months after transplant, 
neither group of mice showed signs of pathology and they had identical levels of total mature 
hematopoietic cells and HSPCs (Fig S2B-E). However, when comparing the contribution of CD45.1+ 
cells versus CD45.2+ cells to the total pool, we observed a significant disadvantage of miR-146a KO 
HSPCs and mature lineages (Fig 2I). Similar to the progressive decline of HSC number, the functional 
quality of HSCs became more and more compromised as miR-146a KO mice aged. When the 
competitive repopulation experiment was carried out with 6-month-old WT and miR-146a KO bone 
marrow cells, at which time increased myeloid and LSK cells and decreased long-term HSCs were 
already evident (Fig S2F), we observed that miR-146a KO cells were completely overwhelmed by 
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their WT counterparts in the recipient mice, with ratios of about one miR-146a KO cell to ten WT cells 
for nearly all mature lineages and HSPCs (Fig S2G). The defective repopulating ability observed in all 
mature and HSPC lineages, including the long-term HSCs, in all three major hematopoietic 
compartments strongly suggests that the defect must originate in the most primitive HSCs. These data 
indicate that miR-146a-deficiency has a detrimental effect on the quality of HSCs under chronic 
inflammatory stress. The functional decline of HSCs in the competitive repopulation setting is evident 
in healthy 8-week-old miR-146a KO mice and becomes significant in 4-month-old mice in the absence 
of any observable pathology, indicating the physiological importance of miR-146a as a guardian of 
HSC quality and longevity.   
 
Hematopoetic-intrinsic and -extrinsic contributions to HSC defects and pathological 
hematopoiesis 
To directly examine both hematopoietic-intrinsic defects and extrinsic factors on hematopoiesis in the 
absence of miR-146a, we performed reciprocal bone marrow transplants, transferring WT bone 
marrow cells into miR-146a KO recipient mice (WT to KO) and KO bone marrow cells into WT 
recipient mice (KO to WT). WT to WT transplant and KO to KO transplant mice were included as 
controls. After 5 months, we harvested all groups for analysis. Interestingly, mice of the WT to WT 
and WT to KO groups had identical levels of HSPCs in their bone marrows and spleens, suggesting 
that the miR-146a-deficient environment is not sufficient to induce significant HSC abnormalities in 
WT cells during this time (Fig 3A-G). In comparison, mice in the KO to WT and KO to KO groups 
both showed 2-3 fold reductions in bone marrow HSCs and myeloid progenitor cells, but not in LSK 
cells (Fig 3A-C), and about a 10-fold increase in spleen HSPCs (Fig 3D-G). As in the miR-146a 
germline KO mice, an increased percentage of LSK cells and a decreased representation of long-term 
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HSCs within the LSK fraction was also observed in these transplantation groups, indicating an 
accelerated process of HSC differentiation (Fig 3H-J). In addition to the HSPC abnormality, mice of 
the KO to WT and KO to KO groups also developed pathological features recapitulating those seen in 
aged miR-146a germline KO mice 19,44. By 5 months post-transplant, 2 out of 8 mice in the KO to KO 
transplant group had succumbed to tumor pathology, including one case of CD4+ T-cell lymphoma in 
the thymus and one case of kidney tumor, with no tumors observed in any of the other groups (Fig 
S3A, B). Necropsy also showed splenomegaly and pale bone marrows in the KO to WT and the KO to 
KO groups (Fig S3C, D). Myeloproliferation was a prominent feature in mice of the KO to WT and 
the KO to KO groups, which showed an increase of spleen weight, number of white blood cells, B 
cells, T cells, and, most dramatically, in the number of CD11b+ or Gr1+ myeloid cells in their spleens, 
compared to the WT to WT and the WT to KO groups (Fig S3E-L). Increased 
myeloproliferation/myelopoiesis was also observed in the bone marrow and peripheral blood (Fig 
S3M, N). Moreover, in line with HSC exhaustion and bone marrow failure, mice of the KO to WT and 
KO to KO groups exhibited hypocellular bone marrow and peripheral cytopenia (Fig S3O-U).  
Overall, these data indicate that it is the miR-146a deficiency in hematopoietic cells that plays 
the dominant role in determining the phenotype of the miR-146a knockout mouse, because transferring 
miR-146a-deficient bone marrow cells into WT environment, but not the reciprocal transfer, is 
sufficient to yield a majority of the phenotypes seen in mice with miR-146a deleted in both 
hematopoietic and non-hematopoietic cells. However, the miR-146a-deficient environment has a 
contributory role to the overall enhanced myelopoiesis because WT bone marrow cells in the KO 
environment gave rise to a mild but significant increase in the number of CD45+ and CD11b+ marrow 
cells and the percentage of CD11b+ and Gr1+ cells in their spleens, compared to the WT to WT mice 
(Fig S3K, L, O, P). More indicative is that when WT bone marrow cells that were transiently 
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transplanted into miR-146a KO environment for 2 months were competed against WT control bone 
marrow cells (Fig 3K), they showed a modest advantage in generating myeloid and lymphoid lineages 
in their spleens, peripheral blood and to a lesser extent bone marrows, while bone marrow HSPCs 
remained unaffected (Fig 3L-O). Overall, these data suggest that it is a hematopoietic-intrinsic 
deficiency of miR-146a that plays the dominant role in driving the HSC defects and pathologic 
myeloproliferation, while the miR-146a deficient environment contributes to the overall phenotype by 
promoting hematopoietic differentiation. In the absence of the driving force from the miR-146a 
deficient environment, lethal tumor pathology and HSC functional decline are attenuated or delayed.   
 
Lymphocytes contribute to the progressive loss of HSCs and myeloproliferative disease 
Although hematopoietic-intrinsic factors play the predominant role in the dysregulated hematopoiesis 
of miR-146a deficient mice, this does not tell us which cell type(s) in the hematopoietic compartment 
might influence aspects of hematopoiesis either through direct interaction or secretion of soluble 
factors. Because miR-146a-deficient lymphocytes display a hyper-activated phenotype with 
dysregulated cytokine production 20, we first determined whether dysregulation of miR-146a-deficient 
lymphocytes might contribute to HSC depletion in miR-146a KO mice. To this end, we crossed mice 
with a targeted deletion of the Rag1 gene, which is required for lymphocyte maturation, with miR-
146a KO mice to generate miR-146a-/-Rag1-/- double knockout mice (miR/Rag1 DKO). When WT, 
miR-146a-/- (miR KO), Rag1-/- (Rag1 KO), and miR/Rag DKO mice were allowed to age for 10 
months, the miR KO mice showed significant depletion of HSPCs (Fig 4A-D), a finding consistent 
with what we have observed previously in an independent examination of WT and miR-146a KO mice 
(Fig 1). Specifically, long-term HSCs and LSK cells in the miR KO marrow were reduced to only 3% 
and 15% of the respective WT levels. In comparison, depletion of HSPCs in miR/Rag1 DKO bone 
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marrow was significantly attenuated. LSK and myeloid progenitor cells in miR/Rag1 DKO bone 
marrow were at levels comparable to those of WT and Rag1 KO mice and long-term HSCs were about 
half of normal (Fig 4A-D). These data indicate that miR-146a-deficient lymphocytes contribute 
substantially to the overall HSPC exhaustion. In addition, miR-146a-deficient lymphocytes were 
shown to be a major driver of the development of bone marrow failure and myeloproliferative disease, 
because miR/Rag1 DKO mice showed normal bone marrow cellularity and an attenuated 
splenomegaly and myeloproliferative phenotype (Fig 4E-L). However, the rescue was not complete 
because miR/Rag1 DKO mice still had mildly enlarged spleens and a 2-3 fold increase in the number 
of total white blood cells and myeloid cells compared to Rag1 KO mice, indicating that miR-146a 
deficiency in myeloid lineages has an intrinsic effect on the development of myeloproliferation (Fig 
4M). It is worth noting that this effect may either be in cis or trans: it could be the proliferating cells 
responding to a changed intracellular milieu or to factors secreted by myeloid cells acting in an 
autocrine or paracrine manner.  
 
NF-κB regulates HSC homeostasis under chronic inflammatory stress 
To understand the molecular mechanism responsible for the stress-induced hematopoiesis, we focused 
on the main pathway known to be regulated by miR-146a, the NF-κB pathway. We have previously 
shown that aging miR-146a KO mice display hyper-activated NF-κB activity that is responsible for the 
development of myeloid malignancy 44. To study whether NF-κB may also regulate HSC homeostasis 
under inflammatory stress, we utilized a transgenic NF-κB-GFP reporter mouse to monitor NF-κB 
activity quantitatively and efficiently in various cell types by measuring GFP fluorescence 104-105. We 
first tested whether NF-κB can be activated in LSK cells and HSCs in 2-month-old WT NF-κB-GFP 
(WT-GFP) reporter mouse under steady state and after LPS stimulation. We found that about 6-7% of 
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WT LSK cells and HSCs had basally activated NF-κB activity, as measured by GFP expression. Six 
hours after LPS challenge in vivo, the percentage of LSK cells and HSCs with activated NF-κB 
increased to more than 25% (Fig S4A). Interestingly, 8-month-old WT-GFP mice also showed an 
increased percentage of LSK cells and HSCs with basal NF-κB activation, compared to 2-month-old 
mice (Fig S4A). These data suggest that both LSK cells and HSCs have functional NF-κB-mediated 
transcription that can be augmented by LPS stimulation and aging. To analyze whether hyper-activated 
NF-κB activity is a feature in miR-146a KO HSPCs, we bred NF-κB-GFP reporter mice with miR-
146a-/- mice to generate NF-κB-GFP+ miR-146a+/+ (WT-GFP), NF-κB-GFP+ miR-146a+/- (miRHET-
GFP), and NF-κB-GFP+ miR-146a-/- (miRKO-GFP) mice. Unperturbed 8-week-old mice of WT-GFP, 
miRHET-GFP, and miRKO-GFP genotypes showed identical levels of basal NF-κB activity (Fig S4B-
D). After repeated LPS stimulation, miRKO-GFP mice, in comparison to WT-GFP and miRHET-GFP 
mice, showed increased percentages of GFP+ cells in various HSPCs (Fig 5A-C) and mature cells in 
their bone marrows, spleens and peripheral blood (Fig S5A-C), demonstrating that chronic 
inflammatory stimulation with bacterial components leads to hyperactivated NF-κB activity in young 
miR-146a-deficient mice.  
To further investigate whether the increased NF-κB activity is responsible for driving HSC 
depletion in bone marrow, we deleted a main subunit of NF-κB, p50, to determine whether reduced 
NF-κB activity in miR-146a-/-p50-/- (miR/p50 DKO) mice might rescue the HSC exhaustion. By 8-9 
months of age, miR/p50 DKO mice still exhibited levels of white blood cells and long-term HSCs 
comparable to that of WT mice, indicating a rescue of the HSC defects (Fig 5D, E). We have 
previously shown that p50 deletion rescues the myeloproliferative disease in 6-month-old miR-146a 
KO mice 44. To determine whether myeloid cancer can also be reversed in miR/p50 DKO mice, we 
aged a cohort of WT, miR KO, p50 KO and miR/p50 DKO mice to about one-and-half years, by 
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which time about 50% of miR-146a KO mice will have developed myeloid cancer. Interestingly, 
miR/p50 DKO mice still showed reduced spleen weight and prolonged survival (Fig S5D, E). The 
incidence of tumors was also significantly reduced in miR/p50 DKO mice, compared to miRKO mice 
(Fig S5F). However, there were two cases of splenic myeloid tumors from a total of 46 miR/p50 DKO 
mice analyzed. Histological analysis of spleens revealed that the majority of miR/p50 DKO spleens, in 
contrast to the miR KO spleens with frequent myeloid sarcoma, showed preserved lymphoid follicular 
structures (Fig S5G). Transplantation of miR/p50 DKO spleen cells into Rag2-/-γC-/- mice did not result 
in splenomegaly or myeloid pathology, although transplanting miRKO splenic tumor cells did (Fig 
S5H and 44. Together, these data show that p50-deficiency significantly ameliorates the 
myeloproliferative and myeloid cancer phenotype in aging miR-146a-/- mice. These findings highlight 
the importance of the NF-κB pathway, particularly the p50 subunit, as the primary mediator of miR-
146a-deficiency-driven myeloproliferation and myeloid tumorigenesis. However, the modest but 
significant increase in spleen weight and the occasional occurrence of myeloid tumors in aging 
miR/p50 DKO mice suggest that other NF-κB subunits or other pathways regulated by miR-146a may 
also be able to mediate the disease phenotype. Overall, we have shown that chronic inflammation-
induced or aging-associated NF-κB activation is responsible for driving HSC exhaustion, 
myeloproliferative disease and myeloid cancer.  
To explore whether the increased proliferation and cycling of miR-146a-deficient HSCs is an 
underlying cause of accelerated HSC depletion under chronic inflammation, we measured BrdU 
incorporation and Ki-67 expression in HSCs after LPS stimulation. Surprisingly, examining 2-month-
old WT and miR-146a KO mice, we did not observe a significant difference in the percentage of 
BrdU+ bone marrow LSK cells and HSCs whether the mice were unperturbed or studied 12 hours after 
a single LPS injection (Fig S5I). However, after repeated LPS stimulation for 3 days, there were 
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significantly higher percentages of BrdU+ and Ki-67+ miR-146a KO LSK cells and HSCs, compared to 
the WT cells, indicating an increased proliferation (Fig 5F, G). Consistent with increased HSC cycling 
and myeloid differentiation, miR-146a KO mice started to show a small but statistically significant 
increase in CD11b+ myeloid cells in their spleens and bone marrows after 3 days of LPS stimulation 
(Fig 5J). It is also interesting to note that identically gated LSK cells and HSCs in spleen seemed to be 
less quiescent than their bone marrow counterparts, as indicated by a higher level of Ki-67 expression 
after LPS stimulation, suggesting that the bone marrow milieu may be a better environment for 
maintaining HSC quiescence during inflammation (Fig 5H). These data show that chronic 
inflammation induces increased HSC proliferation and cycling in miR-146a KO mice and underscores 
the particular importance of miR-146a in modulating HSC activity during chronic inflammation, as 
opposed to in an acute setting. Taken together, these data demonstrate that NF-κB regulates HSC 
activity by promoting HSC proliferation and myeloid differentiation during inflammation; in the 
absence of miR-146a, chronic dysregulated NF-κB activity leads to pathological HSC exhaustion, 
bone marrow failure and myeloid malignancies.  
 
Pro-inflammatory cytokine IL-6 is a culprit NF-κB-responsive gene mediating HSC depletion 
and myeloproliferation 
Pro-inflammatory cytokines, such as IL-6 and TNFα, both of which are highly upregulated upon NF-
κB activation, can be potent oncogenic factors, especially in epithelial cancers 106. More importantly, 
over-expression of IL-6 in bone marrow cells in mice results in myeloproliferative or 
lymphoproliferative disease 107-108. Because we have shown the importance of NF-κB signaling in 
regulating HSC activity and in promoting HSC depletion and myeloproliferation in miR-146a-
deficient mice, we wanted to determine whether this involves many NF-κB-activated genes acting 
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together or if there are key culprit genes. Because of the overwhelmingly large list of NF-κB-
responsive genes, we focused on the pro-inflammatory cytokines that were overproduced in miR-146a-
/- mice, believing that miR-146a-deficient mice likely suffer from a chronic inflammation-driven 
process.  
IL-6 and TNFα are both upregulated in aging mR-146a -/- mice 19,44. However, upregulation of 
TNFα was only prominent in miR-146a-/- spleens that have developed myeloid sarcomas, but not in 
ones without overt tumors, suggesting that TNFα upregulation may be a quite late event in 
oncogenesis. To evaluate the temporal relationship between the increase in inflammatory cytokines 
and the onset of HSC exhaustion and myeloproliferation, we examined younger, 6-10 month-old, 
mice. At this time, the HSC depletion and myeloproliferative phenotype start to become prominent but 
no overt splenic tumors have developed. Similar to what was observed in 18-month-old mice, IL-6 
expression was upregulated in both spleen and bone marrow cells of miR KO mice, compared to WT 
mice. Importantly, miR/p50 DKO mice showed a level of IL-6 comparable to that of WT mice (Fig. 
6A, B). However, the same trend was not observed for TNFα expression at this age (Fig. S6A). 
Furthermore, when bone-marrow-derived macrophages (BMMs) from 8-week-old mice were 
stimulated with LPS in vitro, IL-6, but not TNFα, showed consistently increased induction in miR KO 
BMMs compared to WT BMMs. Interestingly, the exaggerated IL-6 induction in miRKO BMMs was 
significantly more prominent with re-stimulation at a time when WT BMMs showed resistance to 
endotoxin re-stimulation (Fig. 6C) 109. This again suggests that miR-146a may be particularly 
important during chronic and repeated inflammatory challenge. In addition, induction of IL-6, but not 
TNFα, in BMMs was highly dependent on p50. In p50-/- BMMs, IL-6 induction was almost completely 
abolished (Fig. 6C and S6B). These data suggest that IL-6 upregulation is an early feature in miR-
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146a-deficiency-driven HSC depletion and myeloproliferation and reduction in the IL-6 level may be 
an important factor underlying the reduced pathology when p50 is deleted.  
Because we have also shown that miR-146a-deficient lymphocytes are involved in the 
development of the HSC defect and myeloproliferation (Fig 4), we asked whether overproduction of 
IL-6 by miR-146a-deficient lymphocytes represents one potential contributing mechanism. When we 
stimulated splenocytes from WT or miR-146a KO mice in vitro with either LPS to activate both T and 
B cells or a combination of anti-CD3 and anti-CD28 to activate T cells specifically, we observed 
increased production of IL-6 by miR-146a KO splenocytes in both conditions (Fig 6D, E). Moreover, 
when we stimulated WT, miR KO, Rag1 KO and miR/Rag1 DKO mice with LPS in vivo, we found an 
exaggerated IL-6 production in the serum of miR KO mice, compared to that of WT mice. In 
comparison, the serum IL-6 level in miR/Rag1 DKO mice was only modestly increased in a non-
statistically significant manner, compared to that of Rag1 KO mice (Fig 6F). However, miR/Rag1 
DKO mice had a higher serum level of IL-6 than WT mice after LPS challenge. Because miR/Rag1 
DKO mice show an attenuated HSC depletion and myeloproliferation, these data suggest that IL-6 is 
only one of the contributing factors and overproduction of IL-6 alone is not sufficient to induce the full 
range of pathologies in miR/Rag1 DKO mice.      
Despite IL-6 overproduction not being sufficient to reproduce the full-blown phenotype of 
HSC depletion and myeloproliferative disease, we examined if exaggerated IL-6 production is a 
required element. To study this, we bred miR-146a-/- mice with mice knocked out for the Il-6 gene. 
MiR-146a-/- IL-6-/- (miR/IL6 DKO) mice were born at the expected Mendelian frequency and appeared 
normal. Unperturbed, young wildtype (WT), miR-146a-/- (miR KO), IL-6-/- (IL6 KO) and miR-146a-/- 
IL-6-/- (miR/IL6 DKO) mice showed similar levels of CD11b+ and Gr1+ myeloid cells in peripheral 
blood, while B cells were slightly reduced in miR/IL6 DKO mice (Fig S6C). When LPS was 
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repeatedly administered in young WT, miR KO and miR/IL6 DKO mice, an accelerated 
myeloproliferative phenotype was observed in miR KO mice that was largely absent in miR/IL6 DKO 
mice. Specifically, the significantly increased spleen weight, total white blood cells, myeloid cells, and 
erythroid precursor cells present in miR KO were all reduced in miR/IL6 DKO mice to levels 
comparable to those of WT mice (Fig. 6G). The same trend was also observed in the peripheral blood 
(Fig. S6D). In the bone marrow, repeated LPS stimulation of WT and miR/IL6 DKO mice induced 
variable hypocellularity. However, the depletion was more severe and consistent in miR KO bone 
marrow (Fig. S6E). Furthermore, when WT, miR KO, IL6 KO and miR/IL6 DKO mice were allowed 
to age to 6-7 months of age, splenomegaly and myeloproliferation observed in miR KO mice were also 
significantly reduced in miR/IL6 DKO mice (Fig 6H and S6F). More interestingly, the accelerated 
differentiation of bone marrow HSCs into LSK cells and myeloid cells and expansion of splenic 
HSPCs seen in miR KO mice were also partially normalized in miR/IL-6 DKO mice (Fig 6I, J). These 
data show that in the absence of IL-6, miR-146a-/- mice display a partially reduced HSC defect and less 
myeloproliferative disease, indicating that upregulation of the NF-κB-responsive pro-inflammatory 
cytokine IL-6 is an important, yet by itself insufficient, driver of the accelerated HSC differentiation 
and myeloproliferative disease in miR-146a-/- mice under chronic inflammatory stress induced by 
aging or repeated bacterial stimulation.  
 
Upregulation of the miR-146a target, TRAF6, results in bone marrow failure  
Two of the best-validated miR-146a targets, TRAF6 and IRAK1, are signal transduction proteins 
upstream of NF-κB activation. To determine whether increased expression of TRAF6 and/or IRAK1 is 
responsible for the observed HSC exhaustion in the absence of miR-146a, we first measured whether 
their expression was de-repressed in miR-146a-deficient bone marrow cells. BMMs from miR-146a 
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KO and WT mice were stimulated with LPS for 48 hours and then re-stimulated with a second dose. 
The transcript level of TRAF6 showed consistent de-repression in miR-146a KO BMMs throughout 
stimulation, while the transcript level of IRAK1 showed perhaps an oscillating pattern but was not 
consistently higher than that of WT BMMs (Fig 7A, B). Furthermore, when various HSPCs from 
young WT and miR-146a KO mice were subjected to RT-qPCR analysis, de-repression of TRAF6 and 
IRAK1 were quite modest in bulk bone marrow cells but were highest in long-term HSCs, suggesting 
that miR-146a may play a particularly important repressive role in HSCs, acting on TRAF6 and 
IRAK1 (Fig 7C).  
To determine the functional consequences of upregulating TRAF6 and IRAK1, we used a 
GFP-expressing retroviral vector to overexpress TRAF6 (pMIG-TRAF6) or IRAK1 (pMIG-IRAK1) in 
bone marrow cells enriched for HSPCs by 5-fluorouracil (5-FU) treatment. A vector expressing an 
irrelevant protein, luciferase, (pMIG-Luc) was used as the control. These vectors can consistently 
overexpress TRAF6 and IRAK1 by 10-fold and 100-fold, respectively, in bone marrow HSPCs (with 
about 50% transduction efficiency) (Fig S7A). After transplantation, we followed the mice for 9 
months. Interestingly, the percent of GFP+ cells in nucleated peripheral blood cells transduced with 
either pMIG-Luc or pMIG-IRAK1 remained stable or was slightly increased, while the GFP 
percentage in the pMIG-TRAF6 group declined from over 40% initially to less than 10% by the end of 
9 months (Fig 7D). Histological analysis of harvested femur bones revealed that TRAF6-expressing 
mice had reduced bone marrow cellularity, compared to the control mice (Fig 7E). Given the lack of 
apparent phenotype in IRAK1-overexpressing mice, we further pursued TRAF6 as the more relevant 
target of miR-146a in the context of HSC biology. When we repeated the bone marrow transplant with 
100% transduced bone marrow cells by sorting the GFP+ cells, mice receiving TRAF6-overexpressing 
bone marrow cells rapidly succumbed to bone marrow failure (Fig 7F). The mice showed severe 
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anemia and reduced numbers of GFP+ white blood cells in their peripheral blood, compared to the 
pMIG-Luc control group (Fig 7G-I). These data indicate that upregulation of TRAF6 in HSPCs results 
in bone marrow failure in mice, thus emphasizing the importance of tightly regulating TRAF6 level in 
HSPCs. This result suggests that derepression of TRAF6 in miR-146a-deficient HSPCs could be 
primarily responsible for driving HSC depletion and bone marrow failure.  
 
Downregulation of miR-146a in human MDS samples 
Myelodysplastic syndromes (MDS) represent a group of human hematopoietic malignancies that are 
thought to originate from HSCs 110. HSCs in MDS patients have a defect in the ability to differentiate 
into mature cells, leading to peripheral cytopenia. MDS also have a predilection to progress to bone 
marrow failure or acute myelogenous leukemia (AML). MiR-146a KO mice recapitulate several key 
characteristics of MDS, including the decline in function of HSCs, peripheral cytopenia, and the 
propensity to progress to bone marrow failure and myeloid malignancy. To assess whether miR-146a-
deficiency might represent a pathogenic feature of MDS, we analyzed the expression of miR-146a in 
bone marrow samples from healthy donors, MDS and AML patients. The cohort of unselected MDS, 
but not AML, samples showed a 4-fold reduction in the level of miR-146a (Fig 7J), suggesting that 
miR-146a-deficiency may be involved in MDS pathogenesis 37,58.    
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DISCUSSION 
In this study, we have shown that a single microRNA, miR-146a, is a critical regulator of HSC 
homeostasis following chronic exposure of mice to LPS or during the aging process. Mice lacking 
miR-146a develop a series of defects that can be accelerated by multiple LPS treatments.  
Extrapolating from this observation, we suggest that the natural exposure of miR-146a KO mice to 
bacteria and other infectious agents may be the cause of the ‘spontaneous’ deterioration of HSC 
function (bone marrow failure), excessive myelopoiesis and tumor formation that is observed in these 
animals. It could well be that the excess myelopoiesis seen in normal mice as they age is a 
consequence of the same process 111-112. One obvious test of these notions, to examine HSC function in 
germ free mice, is not feasible because of the many secondary consequences of completely ablating the 
normal microbiota and will require more subtle approaches. The remarkable circumstance that a single 
microRNA plays such a crucial role in this process has allowed us to uncover it.  
Because of the existence of mice lacking miR-146a we were able to use mouse genetics to elucidate 
the pathway by which miR-146a functions. Consistent with data from studies of the function of this 
microRNA in other cell types, in HSCs it acts to control NF-κB. We could see NF-κB activated in cells 
from LPS-treated mice and could show that deletion of the NF-κB subunit p50 ameliorated the 
symptoms evident in the miR-146a KO mice. The exact locus of its action appears to be modulation of 
TRAF6 expression because overproduction of TRAF6 caused symptoms similar to those seen in the 
KO. The other validated target of miR-146a, IRAK1, did not appear very involved in the pathology we 
studied here because it was not consistently elevated in the miR-146a KO and its overproduction did 
not produce much symptomatology. NF-κB activates many genes but we found that IL-6 is a very 
important mediator of the pathology of the miR-146a KO. This suggests the following pathway of 
action of miR-146a: infections or other perturbations activate NF-κB in HSCs through TRAF6 and 
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other signal transducers; the basal and NF-κB-enhanced levels of miR-146a then limit the amount of 
TRAF6, allowing the system to quickly return to basal NF-κB activity when the danger has passed; the 
transient NF-κB activation causes a transient increase in IL-6 and the IL-6 acts on the stem and 
progenitor cells causing them to transiently differentiate into myeloid cells. Lacking miR-146a, the 
action of NF-κB is extended, the production of IL-6 is exaggerated, the myelopoietic stress on the 
HSPCs is extended and the over time the pathological symptoms of continual myelopoiesis, bone 
marrow failure and cancer emerge. This may be a pathway in humans that leads to myelodysplastic 
syndrome.       
The function of individual miRNAs in the most primitive hematopoietic stem cells is relatively 
unexplored, except in the case of miR-125 family, which is enriched in the long-term HSCs and can 
positively regulate HSC number and long-term HSC output 14,113. In this study, we added miR-146a to 
the list of genes that regulate HSC homeostasis during chronic inflammation and aging. The function 
of miR-146a in this context seems to be through the regulation of TRAF6, a validated target of miR-
146a in macrophages/monocytes and T cells 19-20. Overexpression of miR-155 also causes pathological 
myelopoiesis similarly to that caused by deletion of miR-146a. MiR-155 appears to act by inhibiting 
the negative-acting phosphatase SHIP 1 70. Enforced expression of TRAF6 in HSPCs results in cell 
death and/or engraftment failure and rapid bone marrow failure, a finding consistent with a previous 
study 37. The same study also showed that overexpression of TRAF6 in HSPCs induced IL-6 
production, which was responsible for some key features of 5q- syndrome, a subtype of MDS. It is 
worth noting that the level of TRAF6 expression in transduced HSPCs is about 10-fold higher than that 
observed in miR-146a-deficient HSCs, and thus the phenotype of enforced TRAF6 overexpression in 
HSPCs is more rapid and dramatic, precluding a careful analysis of HSC function and activity. It will 
be interesting to develop a system to modulate the level of TRAF6 overexpression in a more controlled 
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manner for HSC analysis and to characterize the effects of downregulating TRAF6 genetically or by 
RNA interference in miR-146a-deficient HSCs. In addition to TRAF6 and IRAK1, STAT1 and RelB 
have been identified as direct targets of miR-146a in regulatory T cells and Ly6Chi monocytes, 
respectively 17,43. Recent studies have provided strong evidence for roles of both IFNα and IFNγ in 
regulating HSC quiescence and proliferation 99,101. As a downstream transcription factor of both types 
of interferons, one might speculate that increased STAT1 may also be contributing to miR-146a-
deficiency-induced HSC proliferation and exhaustion. Our preliminary analysis has shown 
upregulation of STAT1 mRNA in miR-146a-deficient HSCs (Fig S7B). A recent study has also 
suggested a role of non-canonical NF-κB activators RelB and NF-κB2 in regulating HSC self-renewal 
114. Whether RelB also contributes to the HSC defect in the context of miR-146a-deficiency remains to 
be determined.  
Under stress-free conditions, NF-κB is not essential for HSC function 102. However, we have 
demonstrated that NF-κB is activated in HSCs during inflammatory stimulation and physiological 
aging. More importantly, in the absence of miR-146a, uncontrolled NF-κB activation in the setting of 
chronic inflammation during long-term aging results in diminished HSC longevity and quality and 
exaggerated myeloid differentiation, ultimately leading to pathological development of HSC 
exhaustion and myeloproliferative neoplasms. The excessive HSC proliferation and myeloid 
differentiation can be accelerated in young miR-146a-deficient mice by repeated inflammatory 
stimulation with bacterial components. Given the multitude of mechanisms involved in 
downregulating NF-κB activity 67,115, these results highlight the critical, non-redundant role of miR-
146a in the negative regulation of NF-κB activity during chronic inflammation. In this way, miR-146a 
acts as a guardian of the functional capabilities and longevity of murine hematopoietic stem cells.  
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In an effort to further characterize the effects downstream of NF-κB activation in the absence 
of miR-146a, we identified IL-6 as one of the culprit NF-κB-reponsive genes. Among its pleiotropic 
functions, IL-6 is a strong stimulator of HSPC proliferation. In addition, IL-6 and its downstream 
transcription factor STAT3 are both important regulators of emergency granulopoiesis 116-117. IL-6 can 
activate NF-κB, forming a positive feed-forward loop, and act through STAT3 to activate additional 
genes involved in cell cycle regulation, proliferation and anti-apoptosis, either directly on HSPCs and 
myeloid cancer cells or indirectly by contributing to the general pro-inflammatory and pro-
proliferative environment. This signaling pathway involving NF-κB/IL-6/STAT3 has been 
demonstrated to be important in the pathogenesis of various epithelial cancers associated with 
inflammation, especially gastrointestinal cancer and breast cancer 106,118-119. Interestingly, a recent 
report shows that chronic myelogenous leukemia (CML) driven by the classic Bcr-Abl oncogenic 
fusion protein can be attenuated by genetic deletion of IL-6 120. It will be interesting to identify the 
genes regulated by NF-κB and STATs that are directly responsible for activating the proliferation and 
differentiation programs within HSPCs and for driving myeloid oncogenesis.  
This study has also identified an important role of dysregulated lymphocytes in driving HSC 
abnormality and myeloproliferative disease in our model, suggesting that autoreactive lymphocytes 
can provide extrinsic stimulus to diseases like bone marrow failure and myeloproliferative 
neoplasms/myelodysplastic syndromes in genetically susceptible hosts. Importantly, systemic 
autoimmunity has long been observed in some MDS patients 121. In addition, given the importance of 
IL-6, a known regulator of CD4 T cell differentiation towards either Th17 or Treg cells, it will be 
interesting to determine whether overproduction of IL-6 contributes to abnormal hematopoiesis by 
altering the ratio of CD4 T cell subsets. Defining the precise role of various lymphocyte subsets, 
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including Th1, Th2, Th17 and Treg cells, using lineage-specific miR-146a knockout mouse may provide 
further insight into how different cell types influence physiologic and pathologic hematopoiesis.  
This study provides an insight into the function of miR-146a and NF-κB in regulating HSC 
proliferation and differentiation under the influence of physiological stressors. In addition, this study 
also has several other important implications. First, it provides direct evidence that prolonged and 
uncontrolled inflammation-driven hematopoiesis can ultimately exhaust the HSC pool and lead to 
myeloid malignancies in genetically susceptible hosts, according nicely with some recent large scale 
epidemiological studies showing that chronic immune stimulation from past infection or autoimmunity 
increases the risk of developing myeloid malignancies, including AML, MDS, and myeloproliferative 
neoplasms (MPN) 122-124. This study provides a possible molecular basis for these intriguing 
epidemiological observations and offers a unique experimental system to further explore the cellular 
and molecular pathways by which infection and autoimmunity can trigger myeloid malignancies; it 
may also provide a way to test potential therapeutic interventions. Second, miR-146a-deficient mice 
represent an excellent model to understand the pathogenesis of MDS, a hematopoietic malignancy of 
older adults (median age of 70 years) 125 that has consistently shown reduced expression of miR-146a. 
Lastly, it suggests that chronic inflammation may be a potential cause of the age-related decline in 
HSC function. Therapeutically, given that many of the cellular and molecular components are 
important in driving the overall pathology, inhibition of p50 subunit of NF-κB, hyperactivated 
lymphocytes, IL-6 overproduction, and TRAF6 represent multiple opportunities for therapeutic 
intervention to disrupt the pathogenic process generating myeloid malignancies, and combinatorial 
inhibition may have even greater therapeutic impact.  
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EXPERIMENTAL PROCEDURES 
Mice. All mice were on a C57BL/6 genetic background and housed under specific pathogen-free 
condition at the California Institute of Technology. All double knockout mice were made by crossing 
single knockout mice. Experiments with mice were approved by the institutional Animal Care and Use 
Committee of the California Institute of Technology. Mouse harvest, tumor analysis, and tumor 
transplant into Rag2-/-γC-/- mice were performed as described 44. For in vivo and in vitro stimulation, 
E. coli 055:B5 LPS (Sigma) was used.  
Cell Culture and Bone Marrow Dervied Macrophages (BMMs). Total bone marrow cells from 
wildtype, miR-146a-/-, or p50-/- mice were lysed with red blood cell lysis buffer (Biolegend) and were 
cultured in DMEM supplemented with 10% (vol/vol) Fetal Bovine Serum (Cellgro), penicillin and 
streptomycin, and M-CSF (20ng/ml) for 6 days. On Day 7, BMMs were stimulated with E. coli 
055:B5 LPS (100ng/ml) for 0, 2, 8, and 24 hours. At 24 hours, BMMs were washed with phosphate 
buffered saline (PBS) and taken off LPS stimulation for 24 hours. At 48 hours, BMMs were re-
stimulated with 100ng/ml LPS for additional 16 hours.  
Flow Cytometry and Sorting. Spleen, bone marrow, and peripheral blood cells were lysed with red 
blood cell lysis buffer (Biolegend). Fluorophore- or biotin-conjugated antibodies against CD45, CD3ε, 
CD4, CD8, CD11b, Gr1, B220, CD19, Ter119, NK1.1, cKit, Sca1, CD48, CD150, EPCR, Ki-67 
(Biolegend or eBioscience) were used for staining. BrdU staining was performed with BrdU staining 
kit from BD Biosciences. Cells were analyzed on a MACSQuant9 or MACSQuant10 Analyzer 
(Miltenyi) for both percentage and cell number. Data analysis was performed with FloJo software 
(TreeStar). Hematopoietic stem and progenitor cell sorting was performed by first depleting lineage+ 
bone marrow cells with magnetic beads (Miltenyi) and then stained with indicated antibodies before 
sorted on a FACSAria machine (BD).  
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Quantitative RT-PCR and ELISA. Total RNA was extracted with TRIzol reagent (Invitrogen) from 
spleen or bone marrow cells after red blood cell lysis. cDNA was synthesized using iScript cDNA 
synthesis kit (Bio-Rad) followed by SYBR Green-based quantatitive PCR (Quantas). Rpl32 was used 
as the normalization gene. MiRNA detection was performed with Taqman RT-qPCR probes (Life 
Technologies). Sno202 was used as the normalization gene. Specific cytokines, including IL-6 and 
TNFα, were measured in cell culture medium or mouse serum by ELISA according to manufacturer’s 
protocol (eBioscience).  
Histopathology. Organs were fixed in 10% neutral-buffered formalin immediately after necropsy. 
After fixation, organs was embedded in paraffin and processed for hematoxylin and eosin (H&E) 
staining. The histolopathological analysis was performed by a board-certified hematopathologist.  
Statistical Analysis. All figures were graphed as mean ± standard error of the mean (SEM). Student 
T-test and Kaplan-Meier survival analysis were performed using GraphPad Prism software. * denotes 
p<0.05, ** denotes p<0.01, *** denotes p<0.001. 
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